EP2069768A2 - Compositions et procédés pour le diagnostic et le traitement du diabète de type 2 - Google Patents

Compositions et procédés pour le diagnostic et le traitement du diabète de type 2

Info

Publication number
EP2069768A2
EP2069768A2 EP07754400A EP07754400A EP2069768A2 EP 2069768 A2 EP2069768 A2 EP 2069768A2 EP 07754400 A EP07754400 A EP 07754400A EP 07754400 A EP07754400 A EP 07754400A EP 2069768 A2 EP2069768 A2 EP 2069768A2
Authority
EP
European Patent Office
Prior art keywords
diabetes
subject
type
diabetic condition
dbmarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07754400A
Other languages
German (de)
English (en)
Other versions
EP2069768A4 (fr
Inventor
Cohava Gelber
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Type Culture Collection ATCC
Original Assignee
American Type Culture Collection ATCC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Type Culture Collection ATCC filed Critical American Type Culture Collection ATCC
Publication of EP2069768A2 publication Critical patent/EP2069768A2/fr
Publication of EP2069768A4 publication Critical patent/EP2069768A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. Furthermore, selected biological markers of the present invention present new targets for therapy and constitute new therapeutics for treatment or prevention of Diabetes.
  • Diabetes mellitus comprises a cluster of diseases distinguished by chronic hyperglycemia that result from the body's failure to produce and/or use insulin, a hormone produced by ⁇ -cells in the pancreas that plays a vital role in metabolism. Symptoms include increased thirst and urination, hunger, weight loss, chronic infections, slow wound healing, fatigue, and blurred vision. Often, however, symptoms are not severe, not recognized, or are absent. Diabetes can lead to debilitating and life-threatening complications including retinopathy leading to blindness, memory loss, nephropathy that may lead to renal failure, cardiovascular disease, neuropathy, autonomic dysfunction, and limb amputation.
  • Diabetes can also Comprise abnormalities of carbohydrate, fat, and protein metabolism attributed to the deficient action of insulin on target tissues resulting from insulin insensitivity or lack of insulin.
  • Type 2 Diabetes is the most common form of Diabetes, which typically develops as a result of a relative, rather than absolute, insulin deficiency, in combination with the body's failure to use insulin properly (also known in the art as "insulin resistance").
  • Type 2 Diabetes often manifests in persons, including children, who are overweight; other risk factors include high cholesterol, high blood pressure, ethnicity, and genetic factors, such as a family history of Diabetes.
  • the majority of patients with Type 2 Diabetes are obese, and obesity itself may cause or aggravate insulin resistance.
  • an increasing number of children are also being diagnosed with Type 2 Diabetes. Due to the progressive nature of the disease, Diabetes complications often develop by the time these children become adults.
  • a study by the American Diabetes Association (ADA) involved 51 children that were diagnosed with Diabetes before the age of 17. By the time these children reached their early 30s, three had kidney failure, one was blind, and two died of heart attacks while on dialysis. This study reinforces the severity of the disease, the serious damage inflicted by Diabetes complications, and the need for early diagnosis of the disease.
  • Diabetes has been rapidly escalating to alarming numbers. Diabetes currently affects approximately 170 million people worldwide with the World Health Organization (WHO) predicting 300 million diabetics by 2025. The United States alone has 20.8 million people suffering from Diabetes (approximately 6% of population and the 6 th most common cause of death). The annual direct healthcare costs of Diabetes worldwide for people in the 20-79 age bracket are estimated at $153-286 billion and is expected to rise to $213-396 billion in 2025.
  • WHO World Health Organization
  • the annual direct healthcare costs of Diabetes worldwide for people in the 20-79 age bracket are estimated at $153-286 billion and is expected to rise to $213-396 billion in 2025.
  • the undiagnosed diabetic population has also continued to increase, primarily because Type 2 Diabetes is often asymptomatic in its early stages, or the hyperglycemia is often not severe enough to provoke noticeable symptoms of Diabetes.
  • Diabetic hyperglycemia can be decreased by weight reduction, increased physical activity, and/or therapeutic treatment modalities.
  • hyperglycemia Several biological mechanisms are associated with hyperglycemia, such as insulin resistance, insulin secretion, and gluconeogenesis, and there are several agents available that act on one or more of these mechanisms, such as but not limited to metformin, acarbose, and rosiglitazone.
  • pre-diabetic state can be present for ten or more years before the detection of glycemic disorders like Diabetes.
  • Treatment of pre-diabetics with therapeutic agents can postpone or prevent Diabetes; yet few pre-diabetics are identified and treated.
  • a major reason, as indicated above, is that no simple laboratory test exists to determ i ne the actual risk of an individual to develop Diabetes.
  • the present invention is premised on the discovery that disease-associated biomarkers can be identified in serum or other bodily fluids long before overt disease is apparent.
  • the presence or absence of these biomarkers from the serum footprints of patients suffering from Type 2 Diabetes precede disruptions in blood glucose control and can be used as early diagno stic tools, for which treatment strategies can be devised and administered to prevent, delay, ameliorate, or reverse irreversible organ damage.
  • One or several of the disease-associated biomarkers of the present invention can be used to diagnose subjects suffering from Type 2 Diabetes or related diseases, or advantageously, to diagnose those subjects who are asymptomatic for Type 2 Diabetes and related diseases.
  • the biomarkers of the present invention can also be used for the design of new therapeutics.
  • the present invention provides a method of diagnosing or identifying type 2 Diabetes or a pre-diabetic condition in a subject, comprising measuring an effective amount of one or more DBMARKERS or a metabolite thereof in a sample from the subject, and comparing the amount to a reference value, wherein an increase or decrease in the amount of the one or more DBMARKERS relative to the reference value indicates that the subject suffers from the type 2 Diabetes or the pre-diabetic condition.
  • the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes or a pre-diabetic condition, or a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.
  • the decrease is at least 10% greater than the reference value. In other embodiments, the increase is at least 10% greater than the reference value.
  • the sample can be urine, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, pancreatic juice, ascites fluid, bone marrow, interstitial fluid, tears, sputum, or saliva.
  • the DBMARKERS of the present invention can be detected electrophoretically, immunochemically, by proteomics technology, or ;by- genomic analysis.
  • the immunochemical detection can be radioimmunoassay, immunoprecipitation, immunoblotting, immunofluorescence assay, or enzyme-linked immunosorbent assay.
  • the proteomics technology can comprise SELDI, IvIALDI, LC/MS, tandem LC/MS/MS, protein/peptide arrays, or antibody arrays-
  • the genomic analysis can comprise polymerase chain reaction (PCR), real-time PCR, microarray analysis, Northern blotting, or Southern blotting.
  • the subject has not been previously diagnosed as having type 2 Diabetes or a pre-diabetic condition.
  • the subject can also be one who has been previously diagnosed as having type 2 Diabetes or a pre-diabetic condition.
  • the subject can be asymptomatic for the type 2 Diabetes or the pre-diabetic condition.
  • Another aspect of the present invention provides a method for monitoring the progression of type 2 Diabetes or a pre-diabetic condition in a subject, comprising (a) detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time, (b) detecting an effective amount of one or more DBMARKERS in a second sample from the subject at a second period of time, and (c) comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
  • the subject has previously been treated for the type 2 Diabetes or the pre-diabetic condition.
  • the first sample is taken from the subject prior to being treated for the type 2 Diabetes or the pre-diabetic condition.
  • the second sample can be taken from the subject after being treated for the type 2 Diabetes or the pre-diabetic condition.
  • the treatment for the type 2 Diabetes or the pre-diabetic condition comprises exercise regimens, dietary supplements, surgical intervention, diabetes-modulating agents, or combinations thereof.
  • the progression of type 2 Diabetes or pre-diabetic conditions can be monitored by detecting changes in body mass index (BMI), insulin levels, blood glucose levels, HDL levels, systolic and/or diastolic blood pressure, or combinations thereof.
  • BMI body mass index
  • a method of monitoring the effectiveness of a treatment regimen for type 2 Diabetes or a pre-diabetic condition in a subject comprising (a) detecting an effective amount of one or more DBMARKERS in a first sample from the subject prior to treatment of the type 2 Diabetes or the pre-diabetic condition, (b) detecting an effective amount of one or more DBMARKERS in a second sample from the subject after treatment of the type 2 Diabetes or the pre-diabetic condition, and (c) comparing the amount of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
  • changes in blood glucose levels can be detected by oral glucose tolerance test.
  • Yet another aspect of the present invention provides a method of treating a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition, comprising detecting an effective amount of one or more DBMARKERS or metabolites thereof present in a first sample from the subject at a first period of time, and treating the subject with one or more diabetes-modulating agents until the amounts of the one or more DBMARKERS or metabolites thereof return to a reference value measured in one or more subjects at low risk for developing type 2 Diabetes or a pre-diabetic condition, or a reference value measured in one or more subjects who show improvements in Diabetes risk factors as a result of treatment with the one or more diabetes-modulating agents.
  • the one or more diabetes-modulating agents comprise sulfonylureas, biguanides, insulin, insulin analogs, peroxisome prolifereator-activated receptor- ⁇ (PPAR- ⁇ ) agonists, dual-acting PPAR agonists, insulin secretagogues, analogs of glucagon-like peptide-1 (GLP-I), inhibitors of dipeptidyl peptidase IV, pancreatic lipase inhibitors, ⁇ -glucosidase inhibitors, or combinations thereof.
  • PPAR- ⁇ peroxisome prolifereator-activated receptor- ⁇
  • GLP-I glucagon-like peptide-1
  • inhibitors of dipeptidyl peptidase IV pancreatic lipase inhibitors
  • ⁇ -glucosidase inhibitors or combinations thereof.
  • the improvements in Diabetes risk factors as a result of treatment with one or more diabetes-modulating agents comprise a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in insulin levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, or combinations thereof.
  • BMI body mass index
  • a method of selecting a treatment regimen for a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition comprising (a) detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time, (b) detecting an effective amount of one or more DBMARKERS in a second sample from the subject at a second period of time, and comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
  • the reference value is derived from one or more subjects who show an improvement in Diabetes risk factors as a result of one or more treatments for type 2 Diabetes or the pre-diabetic condition.
  • Another aspect of the present invention provides a method of evaluating changes in the risk of developing type 2 Diabetes or a pre-diabetic condition in a subject, comprising (a) detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time, (b) detecting an effective amount of one or more DBMARKERS in a second sample from the subject at a second period of time, and comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
  • a method of identifying one or more complications related to type 2 Diabetes in a subject comprising measuring an effective amount of one or more DBMARKERS or a metabolite thereof in a sample from the subject and comparing the amount to a reference value, wherein an increase or decrease in the amount of the one or more DBMARKERS relative to the reference value indicates that the subject suffers from or is at risk for developing complications related to type 2 Diabetes.
  • the complications comprise retinopathy, blindness, memory loss, nephropathy, renal failure, cardiovascular disease, neuropathy, autonomic dysfunction, hyperglycemic hyperosmolar coma, or combinations thereof.
  • the reference value comprises an index value, a value derived from one or more diabetes risk- prediction algorithms or computed indices, a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a value derived from a subject previously identified as having one or more complications related to type 2 Diabetes.
  • Another aspect of the present invention provides a type 2 Diabetes reference expression profile, comprising a pattern of expression levels of one or more DBMARKERS detected in one or more subjects who are not diagnosed with or identified as suffering from type 2 Diabetes.
  • the present invention provides a pre-diabetic condition reference expression profile, comprising a pattern of expression levels of one or more DBMARKERS detected in one or more subjects who are not diagnosed with or identified as suffering from a pre-diabetic condition.
  • the invention also provides a type 2 Diabetes subject expression profile, comprising a pattern of expression levels detected in one or more subjects diagnosed with or identified as suffering from type 2 Diabetes, are at risk for developing type 2 Diabetes, or are being treated for type 2 Diabetes.
  • the present invention also provides a pre-diabetic condition subject expression profile, comprising a pattern of expression levels detected in one or more subjects diagnosed with or identified as suffering from a pre-diabetic condition, are at risk for developing a pre-diabetic condition, or are being treated for a pre-diabetic condition.
  • the present invention also provides a kit comprising DBMARKER detection reagents that detect one or more DBMARKERS, a sample derived from a subject having normal glucose levels, and optionally instructions for using the reagents to generate the expression profiles disclosed herein.
  • the detection reagents can be, for example, one or more antibodies or fragments thereof, one or more aptamers, one or more oligonucleotides, or combinations thereof.
  • a pharmaceutical composition for treating type 2 Diabetes or a pre-diabetic condition in a subject comprising a therapeutically effective amount of one or more DBMARKERS or a metabolite thereof, and a pharmaceutically acceptable carrier or diluent
  • the DBMARKER metabolite comprises SEQ ID NO: 1.
  • the DBMARKER metabolite comprises at least 5, at least 10, at least 15, or at least 20 contiguous amino acid residues of SEQ ID NO: 1.
  • the DBMARKER metabolite can comprise an amino acid sequence at least 90% identical to SEQ ID NO: 1.
  • the present invention also provides a pharmaceutical composition consisting essentially of SEQ ID NO: 1 and a pharmaceutically acceptable carrier or diluent.
  • a method of treating type 2 Diabetes or a pre-diabetic condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical compositions of the invention.
  • Figure 1 represents a protein expression profile of pancreatic extracts from Cohen diabetic resistant (CDr) and sensitive (CDs) rats fed regular diet (RD) or copper-poor high- sucrose diet (HSD).
  • Total protein extract (5 ⁇ g) was prepared under reducing conditions and run on a 4-12% polyacrylamide gel.
  • Figure 2 A is a graphical comparison of serum samples from CDr-RD, CDs-RD, CDr- HSD, and CDs-HSD on a SELDI QlO anion exchange surface chip.
  • a median peak is present in CDr-RD and CDr-HSD (marked by an arrow), but not in CDs-RD and CDs-HSD.
  • a protein fragment from this differentially expressed peak was identified as the C-terminal fragment of Serpina 3M.
  • Figure 2B is an MS/MS spectrum of the 4.2 kilodalton fragment identified by SELDI.
  • Figure 3 A depicts a BLAST alignment of the 38-amino acid Serpina 3M (also referred to as "D3") peptide and .proteins identified as having similar sequence identity.
  • Figure 3B shows a BLAST alignment of nucleic acid sequences encoding the 38-amino acid Serpina 3M peptide and proteins identified in 3A.
  • Figure 3C is a photograph of an agarose gel displaying the results of an RT-PCR experiment using degenerate primers designed to detect the conserved amino acid motifs found in the BLAST alignments of Figures 3 A and 3B.
  • Figure 4 A is a photograph of two-dimensional maps of CDr-RD, CDs-RD, CDr-HSD and
  • CDs-HSD serum samples analyzed by the 2D/LC fractionation system The intensity of the blue bands represents the relative protein amount as detected at 214 nm by UV absorbance.
  • Figure 4B shows a differential second-dimensional reverse-phase HPLC elution profile of CDr-RD (red) versus CDs-RD (green) of a selected first-dimensional isoelectric point fraction (Fraction 31). Proteins that were uniquely identified in CDs-RD samples are listed at the bottom of the graph.
  • Figure 5 ' A is a photograph of a protein gel representing differential protein profiling of CD rat serum samples using two-dimensional gel electrophoresis (2DE). The pH for the first dimension chromatofocusing was from pH 5-8, and the second dimensional separation used a 4- 20% Tris-HCl SDS-PAGE gel. The gel was stained with BioSafe Coomassie Staining (Bio-Rad) 5 for visualization.
  • Figure 5B is a magnified view of the spots identified in Figure 5 A.
  • Figure 6 comprises graphical representations illustrating differentially expressed proteins found in the Cohen Diabetic rat models using 2DE.
  • Figure 7 is a histogram depicting the differentially expressed Cohen Diabetic rat serum 10 . proteins identified by 2DE.
  • Figure 8 is a photograph of Western blots depicting the reactivity of the D3- hyperimmune rabbit serum with the ⁇ 4kD protein fragment present in CDr-RD and CDr-HSD rat serum.
  • a higher molecular weight doublet in the range of 49 and 62 kD • .
  • the hyperimmune sera indicating that a parent protein (and a protein complex) ,15 is expressed by all strains under both RD and HSD treatment modalities, while the derivative of smaller size is differentially expressed only in the CDr strain.
  • the right photograph shows a Western blot membrane incubated in the absence of the D3 hyperimmune rabbit serum.
  • Figure 9 depicts the concentration of the D3 peptide in CDr rat serum as calculated from 20 SELDI analysis.
  • Figure 10 are photographs of gels containing liver extracts (10 ⁇ g), which was probed with secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (HRP)(1 :25000 dilution), in the presence (right panel) or absence (left panel) of primary anti-D3 serum antibody (1:200 dilution).
  • 25 Figure 11 is a photograph of a Western blot analyzing human sera using D3 hyperimmune serum from rabbits. Lane 1 corresponds to the molecular weight marker. Lanes 2-7 represent fractions of a single serum sample from a normal individual (3045 NGT). Lanes 10-14 represent fractions of a single serum sample from a Type 2 Diabetes patient (291).
  • Figures 12A and 12B show preparative gels that were run with 100 ⁇ g of CDr-HSD and 30 CDs-HSD pancreatic extracts, respectively.
  • the positive control was stained with 20 ⁇ g of anti- actin antibody, and the subclone lanes were stained with 600 ⁇ l of conditioned culture supernatant.
  • Figure 13 depicts the results of whole human serum profiled on an anionic QlO protein chip by SELDI.
  • Figure 14 is a photograph of a pseudogel showing the differentially expressed protein peaks identified in 13 T2D and 16 normal human serum samples.
  • the average peak intensity for T2D samples was 2.6, while for normal samples, the average peak intensity was 22.2. The difference between the two samples was about 9-fold.
  • the average intensity for T2D samples was 4.4, and the average intensity for normal samples was 3.3. The relative intensity ratio was 1.47.
  • Figure 15 is a photograph of a pseudogel showing the differentially expressed protein peaks identified in 13 T2D and 16 normal human serum samples.
  • the average peak intensity for T2D samples was 118, while for normal samples, the average peak intensity was 182.
  • the ratio of relative intensity was 0.65.
  • Each dot represents the intensity of the protein peak measured in individual samples.
  • Figure 16 are graphs depicting differential albumin profiling in samples obtained from obese T2D subjects (Dr. Cheatham's samples) vs. non-obese T2D subjects (Dr. Dankner's samples).
  • Figures 17A and 17B are graphical representations of ELISA reactivity of CDs-HSD and CDr-HSD specific hybridoma colonies, as measured by absorbance at O.D. 450 nm.
  • Figures 18A 5 18B, and 18C are photographs of Western blots depicting the reactivity of the CDs-HSD and CDr-HSD specific hybridoma clones P2-10-B8-KA8, P1-14-A2-E-H8, P2-4- H5-K-B4, P1-20-B7-F-C1, P2-13-A9-P-A8, and P1-5-F11-XF5.
  • Figure 19 is a photograph of a Coomassie-stained SDS-polyacrylamide gel following immunoprecipitation with the specific hybridoma clones derived from CDs-HSD and CDr-HSD.
  • Figure 2OA and 2OB are screenshots of an MS spectrum analysis of the lower bands excised from the SDS-PAGE gel in Figure 18. A positive identification of the lower band as calnexin was made.
  • Figure 21 is a scatter plot of the 137 differentially expressed genes in Cohen Type 2 Diabetes rat pancreas. Both upregulated and downregulated genes are shown on the plot.
  • Figure 22A depicts Gene Tree microarray analysis of 12,729 genes present in Cohen Type 2 Diabetes rat pancreas.
  • Figure 22B depicts Gene Tree microarray analysis of the 820 genes that were found to have 2-fold changes in expression, and the 137 genes shown to have 3-fold changes in expression in Cohen Type 2 Diabetes rat pancreas.
  • Figure 22C depicts the Sets 1-5 of the 137 genes exhibiting 3-fold changes in expression, as classified by K-mean clustering.
  • the present invention relates to the identification of biomarkers associated with subjects having Diabetes or a pre-diabetic condition, or who are pre-disposed to developing Diabetes or a pre-diabetic condition. Accordingly, the present invention features diagnostic and prognostic methods for ' identifying subjects who are pre-disposed to developing Diabetes or a pre-diabetic condition, including those subjects who are asymptomatic for Diabetes or a pre-diabetic condition by detection of the biomarkers disclosed herein.
  • the biomaxkers can also be used advantageously to identify subjects having or at risk for developing complications relating to Type 2 Diabetes.
  • biomarkers are also useful for monitoring subjects undergoing treatments and therapies for Diabetes or pre-diabetic conditions, and for selecting therapies and treatments that would be effective in subjects having Diabetes or a pre-diabetic condition, wherein selection and use of such treatments and therapies slow the progression of Diabetes or pre-diabetic conditions, or substantially delay or prevent its onset.
  • the biomarkers of the present invention can be in the form of a pharmaceutical composition used to treat subjects having type 2 Diabetes or related conditions.
  • an active agent or "a pharmacologically active agent” includes a single active agent as well as two or more different active agents in combination
  • reference to "a carrier” includes mixtures of two or more carriers as well as a single carrier, and the like.
  • Diabetes Mellitus in the context of the present invention encompasses Type 1 Diabetes, both autoimmune and idiopathic and Type,2 Diabetes (together, “Diabetes”).
  • the World Health, Organization defines the diagnostic value of fasting plasma glucose concentration to 7.0 mmol/1 (126 mg/dl) and above for Diabetes Mellitus (whole blood 6.1 mmol/1 or 110 mg/dl), or 2-hour glucose level >11.1 mmol/L (>200 mg/dL).
  • Other values suggestive of or indicating high risk for Diabetes Mellitus include elevated arterial pressure > 140/90 mm Hg; elevated plasma triglycerides (>1.7 mmol/L; 150 mg/dL) and/or low HDL-cholesterol ( ⁇ 0.9 mmol/L, 35 mg/dl for men; ⁇ 1.0 mmol/L, 39 mg/dL women); central obesity (males: waist to hip ratio >0.90; females: waist to hip ratio > 0.85) and/or body mass index exceeding 30 kg/m 2 ; microalbuminuria, where the urinary albumin excretion rate >20 ⁇ g/min or albumin: creatinine ratio > 30 mg/g).
  • pre-diabetic condition refers to a metabolic state that is intermediate between normal glucose homeostasis, metabolism, and states seen in frank Diabetes Mellitus.
  • Pre-diabetic conditions include, without limitation, Metabolic Syndrome ("Syndrome X"), Impaired Glucose Tolerance (IGT), and Impaired Fasting Glycemia (IFG).
  • IGT refers to post-prandial abnormalities of glucose regulation
  • IFG refers to abnormalities that are measured in a fasting state.
  • the World Health Organization defines values for IFG as a fasting plasma glucose concentration of 6.1 mmol/L (100 mg/dL) or greater (whole blood 5.6 mmol/L; 100 mg/dL), but less than 7.0 mmol/L (126 mg/dL)(whole blood 6.1 mmol/L; 110 mg/dL).
  • NEP National Cholesterol Education Program
  • IGT paired glucose tolerance
  • a subject with IGT will have two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol) on the 75 g oral glucose tolerance test. These glucose levels are above normal but below the level that is diagnostic for Diabetes.
  • Subjects with impaired glucose tolerance or impaired fasting glucose have a significant risk of developing Diabetes and thus are an important target group for primary prevention.
  • Insulin resistance refers to a condition in which the cells of the body become resistant to the effects of insulin, that is, the normal response to a given amount of insulin is reduced. As a result, higher levels of insulin are needed in order for insulin to exert its effects.
  • “Complications related to type 2 Diabetes” or “complications related to a pre-diabetic condition” can include, without limitation, diabetic retinopathy, diabetic nephropathy, blindness, memory loss, renal failure, cardiovascular disease (including coronary artery disease, peripheral artery disease, cerebrovascular disease, atherosclerosis, and hypertension), neuropathy, autonomic dysfunction, hyperglycemic hyperosmolar coma, or combinations thereof.
  • “Normal glucose levels” is used interchangeably with the term “normoglycemic” and refers to a fasting venous plasma glucose concentration of less than 6.1 mmol/L (110 mg/dL).
  • a baseline value, index value, or reference value in the context of the present invention and defined herein can comprise, for example, "normal glucose levels.”
  • biomarkers have been identified as having altered or modified presence or concentration levels in subjects who have Diabetes, or who exhibit symptoms characteristic of a pre-diabetic condition, such as those subjects who are insulin resistant, have altered beta cell function or are at risk of developing Diabetes based upon known clinical parameters or risk factors, such as family history of Diabetes, low activity level, poor diet, excess body weight (especially around the waist), age greater than 45 years, high blood pressure, high levels of triglycerides, HDL cholesterol of less than 35, previously identified impaired glucose tolerance, previous Diabetes during pregnancy ("gestational Diabetes Mellitus”) or giving birth to a baby weighing more than nine pounds, and ethnicity.
  • biomarkers and methods of the present invention allow one of skill in the art to identify, diagnose, or otherwise assess those subjects who do not exhibit any symptoms of Diabetes or a pre-diabetic condition, but who nonetheless may be at risk for developing Diabetes or experiencing symptoms characteristic of a pre-diabetic condition.
  • biomarker in the context of the present invention encompasses, without limitation, proteins, peptides, nucleic acids, polymorphisms of proteins and nucleic acids, splice variants, fragments of proteins or nucleic acids, elements, metabolites, and other analytes. Biomarkers can also include mutated proteins or mutated nucleic acids.
  • analyte can mean any substance to be measured and can encompass electrolytes and elements, such as calcium.
  • biomarkers can also refer to non-analyte physiological markers of health status encompassing other clinical characteristics such as, without limitation, age, ethnicity, diastolic and systolic blood pressure, body-mass index, and resting heart rate.
  • Proteins, peptides, nucleic acids, polymorphisms, and metabolites whose levels are changed in subjects who have Diabetes or a pre-diabetic condition, or are predisposed to developing Diabetes or a pre-diabetic condition are summarized in Table 1 and are collectively referred to herein as, inter alia, "Diabetes-associated proteins", “DBMARKER polypeptides", or “DBMARKER proteins”.
  • the corresponding nucleic acids encoding the polypeptides are referred to as “Diabetes-associated nucleic acids”, “Diabetes-associated genes”, “DBMARKER nucleic acids”, or “DBMARKER genes”.
  • DBMARKER Diabetes-associated proteins
  • Diabetes-associated nucleic acids are meant to refer to any of the sequences disclosed herein.
  • the corresponding metabolites of the DBMARKER proteins or nucleic acids can also be measured, herein referred to as “DBMARKER metabolites”.
  • DBMARKER indices Proteins, nucleic acids, polymorphisms, mutated proteins and mutated nucleic acids, metabolites, and other analytes are, as well as common physiological measurements and indices constructed from any of the preceding entities, are included in the broad category of "DBMARKERS".
  • DBMARKER of interest which has a molecular weight of about 4.2kD and was further identified as a C-terminal fragment of a serine protease inhibitor, Serpina 3M. This marker was shown to be upregulated in CDr-RD and CDr-HSD rats. Amino acid sequencing of this fragment revealed that this fragment comprises the amino acid sequence SGRPPM ⁇ VWFNRPFLIAVSHTHGQTILFMAKVINPVGA (SEQ ID NO: 1)
  • a DBMARKER “metabolite” in the context of the present invention comprises a portion of a full length polypeptide. No particular length is implied by the term "portion.”
  • a DBMARKER metabolite can be less than 500 amino acids in length, e.g., less than or equal to 400, 350, 300, 250, 200, 150, 100, 75, 50, 35, 26, 25, 15, or 10 amino acids in length.
  • An exemplary DBMARKER metabolite includes a peptide, which can include (in whole or in part) the sequence of SEQ ID NO:1.
  • the DBMARKER metabolite includes at least 5, 10, 15, 20, 25 or more contiguous amino acids of SEQ ID NO:1.
  • a "subject" in the context of the present invention is preferably a mammal.
  • the mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of Diabetes Mellitus or pre-diabetic conditions.
  • a subject can be male or female.
  • a subject can be one who has been previously diagnosed with or identified as suffering from or having Diabetes or a pre-diabetic condition, and optionally, but need not have already undergone treatment for the Diabetes or pre-diabetic condition.
  • a subject can also be one who is not suffering from type 2 Diabetes or a pre-diabetic condition.
  • a subject can also be one who has been diagnosed with or identified as suffering from type 2 Diabetes or a pre- diabetic condition, but who show improvements in known Diabetes risk factors as a result of receiving one or more treatments for type 2 Diabetes or the pre-diabetic condition.
  • a subject can also be one who has not been previously diagnosed as having Diabetes or a pre- diabetic condition.
  • a subject can be one who exhibits one or more risk factors for Diabetes or a pre-diabetic condition, or a subject who does not exhibit Diabetes risk factors, or a subject who is asymptomatic for Diabetes or a pre-diabetic condition.
  • a subject can also be one who is suffering from or at risk of developing Diabetes or a pre-diabetic condition.
  • a subject can also be one who has been diagnosed with or identified as having one or more complications related to type 2 Diabetes or a pre-diabetic condition as defined herein, or alternatively, a subject can be one who has not been previously diagnosed with or identified as having one or more complications related to type 2 Diabetes or a pre-diabetic condition.
  • sample in the context of the present invention is a biological sample isolated from a subject and can include, for example, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, lymphatic fluid, pancreatic juice, ascites fluid, interstitital fluid (also known as "extracellular fluid” and encompasses the fluid found in spaces between cells, including, inter alia, gingival crevicular fluid), bone marrow, sputum, saliva, tears, or urine.
  • One or more, preferably two or more DBMARKERS can be detected in the practice of the present invention. For example, one (1), two (2), five (5), ten (10), fifteen (15), twenty (20), twenty-five (25), thirty (30), thirty-five (35), forty (40), forty-five (45), fifty (50), fifty-five (55), sixty (60), sixty-five (65), seventy (70), seventy-five (75), eighty (80), eighty-five (85), ninety
  • DBMARKERS can be detected.
  • all 158 DBMARKERS disclosed herein can be detected.
  • Preferred ranges from which the number of DBMARKERS can be detected include ranges bounded by any minimum selected from between one and 158, particularly two, five, ten, fifteen, twenty, twenty-five, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred, one hundred and ten, one hundred and twenty, one hundred and thirty, one hundred and forty, one hundred and fifty, paired with any maximum up to the total known
  • DBMARKERS particularly one, two, five, ten, twenty, and twenty-five. Particularly preferred ranges include one to two (1-2), one to five (1-5), one to ten (1-10), one to fifteen (1-15), one to twenty (1-20), one to twenty-five (1-25), one to thirty (1-30), one to thirty-five (1-35), one to forty (1-40), one to forty-five (1-45), one to fifty (1-50), one to fifty-five (1-55), one to sixty (1- 60), one to sixty-five (1-65), one to seventy (1-70), one to seventy-five (1-75), one to eighty (1- 80), one to eighty-five (1-85), one to ninety (1-90), one to ninety-five (1-95), one to one hundred (1-100), one to one hundred and twenty (1-120), one to one hundred and twenty-five (1-125), one to one hundred and thirty (1-130), one to one hundred and forty (1-140), one to one hundred and fifty (1-150), one to one hundred and fifty-eight
  • the risk of developing Diabetes or Pre-diabetic condition can be detected by examining
  • An “effective amount” can be the total amount or levels of DBMARKERS that are detected in a sample, or it can be a "normalized” amount, e.g., the difference between DBMARKERS detected in a sample and background noise.
  • L5 Normalization methods and normalized values will differ depending on the method of detection.
  • mathematical algorithms can be used to combine information from results of multiple individual DBMARKERS into a single measurement or index.
  • Subjects identified as having an increased risk of Diabetes or a pre-diabetic condition can optionally be selected to receive treatment regimens, such as administration of prophylactic or therapeutic compounds such as 0 "diabetes-modulating agents" as defined herein, or implementation of exercise regimens or dietary supplements to prevent or delay the onset of Diabetes or a pre-diabetic condition.
  • a sample isolated from the subject can comprise, for example, blood, plasma, blood cells, endothelial cells, tissue biopsies, lymphatic fluid, pancreatic juice, serum, bone marrow, ascites fluid, interstitial fluid (including, for example, gingival crevicular fluid), urine, sputum, saliva, 5 tears, or other bodily fluids.
  • the amount of the DBMARKER protein, peptide, nucleic acid, polymorphism, metabolite, or other analyte can be measured in a test sample and compared to the normal control . level.
  • the term "normal control level" means the level of one or more DBMARKER proteins, nucleic acids, polymorphisms, metabolites, or other analytes, or DBMARKER indices, typically 0 found in a subject not suffering from Diabetes or a pre-diabetic condition and not likely to have Diabetes or a pre-diabetic condition, e.g., relative to samples collected from longitudinal studies of young subjects who were monitored until advanced age and were found not to develop Diabetes or a pre-diabetic condition.
  • the "normal control level” can encompass values obtained from a subject having "normal glucose levels” or “normoglycemic levels” as defined herein.
  • the normal control level can mean the level of one or more DBMARKER protein, peptide, nucleic acid, polymorphism, metabolite, or other analyte typically found in a subject suffering from Diabetes or a pre-diabetic condition.
  • the normal control level can be a range or an index.
  • the normal control level can be a database of patterns from previously tested subjects.
  • a change in the level in the subject-derived sample of one or more DBMARKER protein, nucleic acid, polymorphism, metabolite, or other analyte compared to the normal control level can indicate that the subject is suffering from or is at risk of developing Diabetes or a pre-diabetic condition.
  • a similar level compared to the normal control level in the subject-derived sample of one or more DBMARKER proteins, nucleic acids, polymorphisms, metabolites, or other analytes can indicate that the subject is not suffering from, is not at risk or is at low risk of developing Diabetes ' or a pre-diabetic condition.
  • a reference value can refer to values obtained from a control subject or population whose diabetic state is known (i.e., has been diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition, or has not been diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition) or can be an index value or baseline value.
  • the reference sample or index value or baseline value may be taken or derived from one or more subjects who have been exposed to the treatment, or may be taken or derived from one or more subjects who are at low risk of developing Diabetes or a pre-diabetic condition, or may be taken or derived from subjects who have shown improvements in Diabetes risk factors as a result of exposure to treatment.
  • the reference sample or index value or baseline value may be taken or derived from one or more subjects who have not been exposed to the treatment.
  • samples may be collected from subjects who have received initial treatment for Diabetes or a pre-diabetic condition and subsequent treatment for Diabetes or a pre-diabetic condition to monitor the progress of the treatment.
  • a reference value can also comprise a value derived from risk prediction algorithms or computed indices from population studies such as those disclosed herein.
  • a reference value can also be a value derived from a subject previously identified as having one or more complications related to type 2 Diabetes or a pre-diabetic condition, or alternatively, a value derived from a subject who has not developed complications, or has not been previously diagnosed with or identified as having complications relating to type 2 Diabetes or a pre-diabetic condition.
  • a reference value can also comprise a value corresponding to the normal control level or derived from one or more subjects having "normal glucose levels" as defined herein.
  • Differences in the level or amounts (which can be an "effective amount") of DBMARKERS measured by the methods of the present invention can comprise increases or decreases in the level or amounts of DBMARKERS.
  • the increase or decrease in the amounts of DBMARKERS relative to a reference value can be indicative of progression of type 2 Diabetes or a pre-diabetic condition, delay, progression, development, or amelioration of complications related to type 2 Diabetes or a pre-diabetic condition, an increase or decrease in the risk of developing type 2 Diabetes or a pre-diabetic condition, or complications relating thereto.
  • the increase or decrease can be indicative of the success of one or more treatment regimens for type 2 Diabetes or a pre-diabetic condition, or can indicate improvements or regression of Diabetes risk factors.
  • the increase or decrease can be, for example, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% of the reference value or normal control
  • the difference in the level (or amounts) of DBMARKERS is preferably statistically significant.
  • Statistically significant it is meant that the alteration is greater than what might be expected to happen by chance alone.
  • Statistical significance can be determined by any method known in the art. For example, statistical significance can be determined by p-vahie.
  • the /7-value is a measure of probability that a difference between groups during an experiment happened by chance. (P(z>zobserved)). For example, a/>-value of 0.01 means that there is a 1 in 100 chance the result occurred by chance. The lower thep-value, the more likely it is that the difference between groups was caused by treatment.
  • An alteration is statistically significant if the /rvalue is at least 0.05.
  • thep-value is 0.04, 0.03, 0.02, 0.01, 0.005, 0.001 or less.
  • achieving statistical significance generally but not always requires that combinations of several DBMARKERS be used together in panels and combined with mathematical algorithms in order to achieve a statistically significant DBMARKER index.
  • the "diagnostic accuracy" of a test, assay, or method concerns the ability of the test, assay, or method to distinguish between subjects having Diabetes or a pre-diabetic condition, or at risk for Diabetes or a pre-diabetic condition is based on whether the subjects have a "clinically significant presence” or a "clinically significant alteration” in the levels of one or more DBMARKERS.
  • ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
  • the present invention may be used to make categorical or continuous measurements of the risk of conversion to Type 2 Diabetes, thus diagnosing a category of subjects defined as pre- Diabetic.
  • the methods of the present invention can be used to discriminate between normal and pre-diabetic condition subject cohorts.
  • the terms "high degree of diagnostic accuracy” and “very high degree of diagnostic accuracy” refer to the test or assay for that DBMARKER (or DBMARKER index; wherein DBMARKER value encompasses any individual measurement whether from a single DBMARKER or derived from an index of DBMARKERS) with the predetermined cut-off point correctly (accurately) indicating the presence or absence of a pre-diabetic condition.
  • a perfect test would have perfect accuracy. Thus, for subjects who have a pre-diabetic condition, the test would indicate only positive test results and would not report any of those subjects as being
  • the present invention may be used to discriminate a pre-diabetic condition from Diabetes, or Diabetes from Normal. Such use may require different subsets of
  • DBMARKERS (OUt of the total DBMARKERS as disclosed in Table 1), mathematical algorithm, and/or cut-off point, but be subject to the same aforementioned measurements of diagnostic accuracy for the intended use.
  • changing the cut point or threshold value of a test usually changes the sensitivity and specificity, but in a qualitatively inverse relationship. For example, if the cut point is lowered, more subjects in the population tested will typically have test results over the cut point or threshold value. Because subjects who have test results above the cut point are reported as having the disease, condition, or syndrome for which the test is conducted, lowering the cut point will cause more subjects to be reported as having positive results (e.g., that they have Diabetes or a pre-diabetic condition). Thus, a higher proportion of those who have Diabetes or a pre-diabetic condition will be indicated by the test to have it.
  • the sensitivity (true positive rate) of the test will be increased.
  • there will be more false positives because more people who do not have the disease, condition, or syndrome (e.g., people who are truly "negative") will be indicated by the test to have DBMARKER values above the cut point and therefore to be reported as positive (e.g., to have the disease, condition, or syndrome) rather than being correctly indicated by the test to be negative.
  • the specificity (true negative rate) .of the test will be decreased.
  • raising the cut point will tend to decrease the sensitivity and increase the specificity.
  • ROC Receiver Operating Characteristics
  • An ROC curve is an x-y plot of sensitivity on the y-axis, on a scale of zero to one (e.g., 100%), against a value equal to one minus specificity on the x-axis, on a scale of zero to one (e.g., 100%). In other words, it is a plot of the true positive rate against the false positive rate for that test, assay, or method.
  • subjects can be assessed using a perfectly accurate or "gold standard" method that is independent of the test, assay, or method in question to determine whether the subjects are truly positive or negative for the disease, condition, or syndrome (for example, coronary angiography is a gold standard test for the presence of coronary atherosclerosis).
  • the subjects can also be tested using the test, assay, or method in question, and for varying cut points, the subjects are reported as being positive or negative according to the test, assay, or method.
  • the sensitivity (true positive rate) and the value equal to one minus the specificity (which value equals the false positive rate) are determined for each cut point, and each pair of x-y values is plotted as a single point on the x-y diagram.
  • the "curve” connecting those points is the ROC curve.
  • the ROC curve is often used in order to determine the optimal single clinical cut-off or treatment threshold value where sensitivity and specificity are maximized; such a situation represents the point on the ROC curve which describes the upper left corner of the single largest rectangle which can be drawn under the curve.
  • the total area under the curve (“AUC") is the indicator that allows representation of the sensitivity and specificity of a test, assay, or method over the entire range of cut points with just a single value.
  • the maximum AUC is one (a perfect test) and the minimum area is one half (e.g. the area where there is no discrimination of normal versus disease). The closer the AUC is to one, the better is the accuracy of the test. It should be noted that implicit in all ROC and AUC is the definition of the disease and the post-test time horizon of interest.
  • a “high degree of diagnostic accuracy” it is meant a test or assay in which the AUC (area under the ROC curve for the test or assay) is at least 0.70, desirably at least 0.75, more desirably at least 0.80, preferably at least 0.85, more preferably at least 0.90, and most preferably at least 0.95.
  • a “very high degree of diagnostic accuracy” it is meant a test or assay in which the AUC (area under the ROC curve for the test or assay) is at least 0.80, desirably at least 0.85, more desirably at least 0.875, preferably at least 0.90, more preferably at least 0.925, and most preferably at least 0.95.
  • ROC and AUC can be misleading as to the clinical utility of a test, and absolute and relative risk ratios as defined elsewhere in this disclosure can be employed to determine the degree of diagnostic accuracy.
  • Populations of subjects to be tested can also be categorized into quartiles, where the top quartile (25% of the population) comprises the group of subjects with the highest relative risk for developing or suffering from Diabetes or a pre-diabetic condition and the bottom quartile comprising the group of subjects having the lowest relative risk for developing Diabetes or a pre-diabetic condition.
  • the top quartile (25% of the population) comprises the group of subjects with the highest relative risk for developing or suffering from Diabetes or a pre-diabetic condition and the bottom quartile comprising the group of subjects having the lowest relative risk for developing Diabetes or a pre-diabetic condition.
  • values derived from tests or assays having over 2.5 times the relative risk from top to bottom quartile in a low prevalence population are considered to have a "high degree of diagnostic accuracy," and those with five to seven times the relative risk for each quartile are considered to have a very high degree of diagnostic accuracy.
  • the predictive value of any test depends on the sensitivity and specificity of the test, and on the prevalence of the condition in the population being tested. This notion, based on Bayes' theorem, provides that the greater the likelihood that the ' condition being screened for is present in a subject or in the population (pre-test probability), the greater the validity of a positive test- and the greater the likelihood that the result is a true positive.
  • pre-test probability the greater the likelihood that the ' condition being screened for is present in a subject or in the population
  • the problem with using a test in any population where there is a low likelihood of the condition being present is that a positive result has limited value (i.e., more likely to be a false positive).
  • a negative test result is more likely to be a false negative.
  • the degree of diagnostic accuracy i.e., cut points on a ROC curve
  • defining an acceptable AUC value determining the acceptable ranges in relative concentration of what constitutes an effective amount of the DBMARKERS of the invention allows one of skill in the art to use the DBMARKERS to diagnose or identify subjects with a pre-determined level of predictability.
  • “Risk” in the context of the present invention can mean “absolute” risk, which refers to that percentage probability that an event will occur over a specific time period. Absolute risk can be measured with reference to either actual observation post-measurement for the relevant time cohort, or with reference to index values developed from statistically valid historical cohorts that have been followed for the relevant time period. "Relative” risk refers to the ratio of absolute risks of a subject's risk compared either to low risk cohorts or average population risk, which can vary by how clinical risk factors are assessed.
  • Odds ratios the proportion of positive events to negative events for a given test result, are also commonly used (odds are according to the formula p/( 1 -p) where p is the probability of event and ( 1 - p) is the probability of no event) to no-conversion:
  • Alternative continuous measures which may be assessed in the context of the present invention include time to Diabetes conversion and therapeutic Diabetes conversion risk reduction ratios.
  • measures of diagnostic accuracy for a calculated index are typically based on linear regression curve fits between the predicted continuous value and the actual observed values (or historical index calculated value) and utilize measures such as R squared, p values and confidence intervals.
  • Such methods include, but are not limited to, measurement of systolic and diastolic blood pressure, measurements of body mass index, in vitro determination of total cholesterol, LDL, HDL, insulin, and glucose levels from blood samples, oral glucose tolerance tests, stress tests, measurement of human serum C-reactive protein (hsCRP), electrocardiogram (ECG), c- peptide levels, anti-insulin antibodies, anti-beta cell-antibodies, and glycosylated hemoglobin (HbAic).
  • hsCRP human serum C-reactive protein
  • ECG electrocardiogram
  • HbAic glycosylated hemoglobin
  • any of the aforementioned methods can be used separately or in combination to assess if a subject has shown an "improvement in Diabetes risk factors.”
  • Such improvements include, without limitation, a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, an increase in insulin levels, or combinations thereof.
  • BMI body mass index
  • OGTT oral glucose tolerance test
  • the OGTT should be administered 5 in the morning after at least 3 days of unrestricted diet (greater than 150 g of carbohydrate daily) and usual physical activity.
  • a reasonable (30-50 g) carbohydrate-containing meal should be .consumed on the evening before the test:
  • the test should be preceded by an overnight fast of 8- 14 hours, during which water may be consumed.
  • the subject After collection of the fasting blood sample, the subject should drink 75 g of anhydrous glucose or 82.5 g of glucose monohydrate in 250-300 0 ml of water over the course of 5 minutes.
  • the test load should be 1.75 g of glucose per kg body weight up to a total of 75 g of glucose. Timing of the test is from the beginning of the drink. Blood samples must be collected 2 hours after the test load.
  • ITT impaired glucose tolerance
  • the rate of conversion over such periods is typically estimated at 5-6%, or less than 1 % per annum.
  • a subject suffering from or at risk of developing Diabetes- or a pre-diabetic condition may also be suffering from or at risk of developing cardiovascular disease, hypertension or obesity.
  • Type 2 Diabetes in particular and cardiovascular disease have many risk factors in common, and many of these risk factors are highly correlated with one another. The relationships among these risk factors may be attributable to a small number of physiological phenomena, perhaps even a single phenomenon.
  • subjects suffering from or at risk of developing Diabetes, cardiovascular disease, hypertension or obesity can be identified by methods known in the art. For example, Diabetes is frequently diagnosed by measuring fasting blood glucose levels or insulin. Normal adult glucose levels are 60-126 mg/dl. Normal insulin levels are 7 mU/ml ⁇ 3mU. Hypertension is diagnosed by a blood pressure consistently at or above 140/90. Risk of cardiovascular disease can also be diagnosed by measuring cholesterol levels.
  • LDL cholesterol above 137 br total cholesterol above 200 is indicative of a heightened risk of cardiovascular disease.
  • Obesity is diagnosed for example, by body mass index.
  • Body mass index (BMI) is measured (kg/m 2 (or- . ⁇ lb/in 2 X 704.5)).
  • waist circumference estimates fat distribution
  • waist-t ⁇ -hip ratio estimates fat distribution
  • skinfold thickness if measured at several sites, estimates fat distribution
  • bioimpedance based on principle that lean mass conducts current better than fat mass (i.e. fat mass impedes current), estimates % fat) can be measured.
  • Overweight individuals are characterized as having a waist circumference of >94 cm for men or >80 cm for women and waist to hip ratios of > 0.95 in men and > 0.80 in women.
  • Obese individuals are characterized as having a BMI of 30 to 34.9, being greater than 20% above "normal" weight for height, having a body fat percentage > 30% for women and 25% for men, and having a waist circumference >102 cm (40 inches) for men or 88 cm (35 inches) for women.
  • Individuals with severe or morbid obesity are characterized as having a BMI of > 35.
  • DBMARKERS and DBMARKER expression profiles of the present invention may overlap or be encompassed by biomarkers of cardiovascular disease, and indeed may be useful in the diagnosis of the risk of cardiovascular disease.
  • Risk prediction for Diabetes Mellitus or a pfe-diabetic condition can also encompass risk prediction algorithms and computed indices that assess and estimate a subject's absolute risk for developing Diabetes or a pre-diabetic condition with reference to a historical cohort. Risk assessment using such predictive mathematical algorithms and computed indices has increasingly been incorporated into guidelines for diagnostic testing and treatment, and encompass indices obtained from and validated with, inter alia, multi-stage, stratified samples from a representative population.
  • a plurality of conventional Diabetes risk factors are incorporated into predictive models.
  • a notable example of such algorithms include the Framingham Heart Study (Ka ⁇ nel, W.B., et al, (1976) Am. J. Cardiol. 38: 46-51) and modifications of the Framingham Study, such as the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), also know as NCEP/ ATP III, which incorporates a patient's age, total cholesterol concentration, HDL cholesterol concentration, smoking status, and systolic blood pressure to estimate a person's 10-year risk of developing cardiovascular disease, which is commonly found in subjects suffering from or at risk for developing Diabetes Mellitus, or a pre- d ⁇ abetic condition.
  • the Framingham algorithm has been found to be modestly predictive of the risk for developing Diabetes Mellitus, or a pre-diabetic condition.
  • Other Diabetes risk prediction algorithms include, without limitation, the San Antonio
  • Archimedes is a mathematical model of Diabetes that simulates the disease state person- by-person, object-by-object and comprises biological details that are continuous in reality, such as the pertinent organ systems, more than 50 continuously interacting biological variables, and the major symptoms, tests, treatments, and outcomes commonly associated with Diabetes.
  • Archimedes includes many diseases simultaneously and interactively in a single integrated physiology, enabling it to address features such as co-morbidities, syndromes, treatments and other multiple effects.
  • the Archimedes model includes Diabetes and its complications, such as coronary artery disease, congestive heart failure, and asthma.
  • the model is written in differential equations, using object-oriented programming and a construct called "features".
  • the model comprises the anatomy of a subject (all simulated subjects have organs, such as hearts, livers, pancreases, gastrointestinal tracts, fat, muscles, kidneys, eyes, limbs, circulatory systems, brains, skin, and peripheral nervous systems), the "features” that determine the course of the disease and representing real physical phenomena (e.g., the number of milligrams of glucose in a deciliter of plasma, behavioral phenomena, or conceptual phenomena (e.g., the "progression” of disease), risk factors, incidence, and progression of the disease, glucose metabolism, signs and tests, diagnosis, symptoms, health outcomes of glucose metabolism, treatments, complications, deaths from Diabetes and its complications, deaths from other causes, care processes, and medical system resources.
  • organs such as hearts, livers, pancreases, gastrointestinal tracts, fat, muscles, kidneys, eyes, limbs, circulatory systems, brains, skin, and peripheral nervous systems
  • real physical phenomena e.g., the number of milligrams of glucose in a deciliter of plasma, behavioral phenomena, or conceptual phenomena (
  • simulated subjects there are thousands of simulated subjects, each with a simulated anatomy and physiology, who will get simulated diseases, can seek care at simulated health care facilities, will be seen by simulated health care personnel in simulated facilities, will be given simulated tests and treatments, and will have simulated outcomes.
  • each of the simulated patients is different, with different characteristics, physiologies,, behaviors, and responses to treatments, all designed to match the individual variations seen in reality.
  • the model is built by development of a non-quantitative or conceptual description of the pertinent biology and pathology — the variables and relationships - as best they are understood with current information.
  • the Finland-based Diabetes Risk Score is designed as a screening tool for identifying high-risk subjects in the population and for increasing awareness of the modifiable risk factors and healthy lifestyle.
  • the Diabetes Risk Score was determined from a random population sample of 35- to 64-year old Finnish men and women with no anti-diabetic drug treatment at baseline, and followed for 10 years. Multivariate logistic regression model coefficients were used to assign each variable category a score.
  • the Diabetes Risk Score comprises the sum of these individual scores and validated in an independent population survey performed in 1992 with a prospective follow-up for 5 years. Age, BMI, waist circumference, history of antihypertensive drug treatment and high blood glucose, physical activity, and daily consumption of fruits, berries, or vegetables were selected as categorical variables.
  • the Finland-based Diabetes Risk Score values are derived from the coefficients of the logistic model by classifying them into five categories.
  • the estimated probability (p) of drug- treated Diabetes over a 10-year span of time for any combination of risk factors can be calculated from the following coefficients:
  • the sensitivity relates to the probability that the test is positive for subjects who will get " drug-treated Diabetes in the future and the specificity reflects the probability that the test is negative for subjects without drug-treated Diabetes.
  • the sensitivity and the specificity with 95% confidence interval (CI) were calculated for each Diabetes Risk Score level in differentiating the subjects who developed drug-treated Diabetes from those who did not.
  • ROC curves were plotted for the Diabetes Risk score, the sensitivity was plotted on the y-axis and the false-positive rate (1 -specificity) was plotted on the x-axis. The more accurately discriminatory the test, the steeper the upward portion of the ROC curve, and the higher the AUC, the optimal cut point being the peak of the curve.
  • the Diabetes Risk Score model comprises a concise model that includes only these statistically significant variables and a full model, which includes physical activity and fruit and vegetable consumption.
  • the San Antonio Heart Study is a long-term, community-based prospective observational study of Diabetes and cardiovascular disease in Mexican Americans and non-Hispanic Caucasians.
  • the study initially enrolled 3,301 Mexican-American and 1,857 non-Hispanic Caucasian men and non-pregnant women in two phases between 1979 and 1988. Participants were 25-64 years of age at enrollment and were randomly selected from low, middle, and high- income neighborhoods in San Antonio, Texas. A 7-8 year follow-up exam followed approximately 73% of the surviving individuals initially enrolled in the study.
  • Baseline characteristics such as medical history of Diabetes, age, sex, ethnicity, BMI, systolic and diastolic blood pressure, fasting and 2-hour plasma glucose levels, fasting serum total cholesterol, LDL, and HDL cholesterol levels, as well as triglyceride levels, were compiled and assessed.
  • a multiple logistic regression model with incident Diabetes as the dependent variable and the aforementioned baseline characteristics were applied as independent variables. Using this model, univariate odds ratios can be computed for each potential risk factor for men and women separately and for both sexes combined. For continuous risk factors, the odds ratios can be presented for a 1-SD increment.
  • a multivariate predicting model with both sexes combined can be developed using a stepwise logistic regression procedure in which the variables that had shown statistically significant odds ratios when examined individually were allowed to enter the model.
  • This multivariable model is then analyzed by ROC curves and 95% CIs of the areas under the ROC curves estimated by non-parametric algorithms such as those described by DeLong (DeLong E.R. et al, (1988) Biometrics 44: 837-45).
  • DeLong DeLong E.R. et al, (1988) Biometrics 44: 837-45.
  • the evidence-based, multiple risk factor assessment approach is only moderately accurate for the prediction of short- and long-term risk of manifesting Diabetes or a pre-diabetic condition in individual asymptomatic or otherwise healthy subjects.
  • risk prediction algorithms can be advantageously used in combination with the DBMARKERS of the present invention to distinguish between subjects in a population of interest to determine the risk stratification of developing Diabetes or a pre-diabetic condition.
  • the DBMARKERS and methods of use disclosed herein provide tools that can be used in combination with such risk prediction algorithms to assess, identify, or diagnose subjects who are asymptomatic and do not exhibit the conventional risk factors.
  • the data derived from risk prediction algorithms and from the methods of the present invention can be compared by linear regression.
  • Linear regression analysis models the relationship between two variables by fitting a linear equation to observed data.
  • One variable is considered to be an explanatory variable, and the other is considered to be a dependent variable.
  • values obtained from the Archimedes or San Antonio Heart analysis can be used as a dependent variable and analyzed against levels of one or more DBMARKERS as the explanatory variables in an effort to more fully define the underlying biology implicit in the calculated algorithm score (see Examples).
  • risk prediction algorithms, or their individual inputs, which are generally DBMARKERS themselves can be directly incorporated into the practice of the present invention, with the combined algorithm compared against actual observed results in a historical cohort.
  • a numerical measure of association between two variables is the "correlation coefficient,”or R, which is a value between -1 and 1 indicating the strength of the association of the observed data for the two variables. This is also often reported as the square of the correlation coefficient, as the "coefficientOf determination" or R 2 ; in this form it is the proportion of the total variation in Y explained by fitting the line.
  • the most common method for fitting a regression line is the method of least-squares.
  • This method calculates the best-fitting line for the observed data by minimizing the sum of the squares of the vertical deviations from each data point to the line (if a point lies on the fitted line exactly, then its vertical deviation is 0). Because the deviations are first squared, then summed, there are no cancellations between positive and negative values. After a regression line has been computed for a group of data, a point which lies far from the line (and thus has a large residual value) is known as an outlier. Such points may represent erroneous data, or may indicate a poorly fitting regression line. If a point lies far from the other data in the horizontal direction, it is known as an influential observation. The reason for this distinction is that these points have may have a significant impact on the slope of the regression line.
  • Linear regression analyses can be used, inter alia, to predict the risk of developing Diabetes or a pre-diabetic condition based upon correlating the levels of one or more DBMARKERS in a sample from a subject to that subjects' actual observed clinical outcomes, or in combination with, for example, calculated Archimedes risk scores, San Antonio Heart risk scores, or other known methods of diagnosing or predicting the prevalence of Diabetes or a pre- diabetic condition.
  • a pre-diabetic condition based upon correlating the levels of one or more DBMARKERS in a sample from a subject to that subjects' actual observed clinical outcomes, or in combination with, for example, calculated Archimedes risk scores, San Antonio Heart risk scores, or other known methods of diagnosing or predicting the prevalence of Diabetes or a pre- diabetic condition.
  • non-linear equations and analyses to determine the relationship between known predictive models of Diabetes and levels of DBMARKERS detected in a subject sample.
  • Factor analysis is a mathematical technique by which a large number of correlated variables (such as Diabetes risk factors) can be reduced to fewer "factors" that represent distinct attributes that account for a large proportion of the variance in the original variables (Hanson, R.L. et al, (2002) Diabetes 51: 3120-3127).
  • factor analysis is well suited for identifying components of Diabetes Mellitus and pre-diabetic conditions such as IGT, IFG, and Metabolic Syndrome.
  • Epidemiological studies of factor "scores” from these analyses can further determine relations between components of the metabolic syndrome and incidence of Diabetes.
  • the premise underlying factor analysis is that correlations observed among a set of variables can be explained by a small number of unique unmeasured variables, or "factors”.
  • Factor analysis involves two procedures: 1) factor extraction to estimate the number of factors, and 2) factor rotation to determine constituents of each factor in terms of the original variables.
  • Factor extraction can be conducted by the method of principal components. These components are linear combinations of the original variables that are constructed so that each component has a correlation of zero with each of the other components. Each principal component is associated with an "eigen-value," which represents the variance in the original variables explained by that component (with each original variable standardized to have a variance of 1). The number of principal components that can be constructed is equal to the number of original variables. In factor analysis, the number of factors is customarily determined by retention of only those components that account for more of the total variance than any single original variable (i.e., those components with eigen-values of >1). Once the number of factors has been established, then factor rotation is conducted to determine the composition of factors that has the most parsimonious interpretation in terms of . the original variables.
  • factor loadings which represent correlations of each ' factor with the original variables, are changed so that these factor loadings are made as close to 0 or 1 as possible (with the constraint that the total amount of variance explained by the factors remains unchanged).
  • a number of methods for factor rotation have been developed and can be distinguished by whether they require the final set of factors to remain uncorrelated with one another (also known as “orthogonal methods") or by whether they allow factors to be correlated (“oblique methods").
  • the pattern of factor loadings is .examined to determine which original variables represent primary constituents of each factor. Conventionally, variables that have a factor loading of >0.4 (or less than -0.4) with a particular . factor are considered to be its major constituents. Factor analysis can be very useful in constructing DBMARKER panels from their constituent components, and in grouping substitutable groups of markers.
  • Comparison can be performed on test ("subject") and reference (“control”) samples measured concurrently or at temporally distinct times.
  • An example of the latter is the use of compiled expression information, e.g., a sequence database, which assembles information about expression levels of DBMARKERS.
  • the reference sample e.g., a control sample is from a subject that does not have Diabetes
  • a similarity in the amount of the DBMARKERS in the subject test sample and the control reference sample indicates that the treatment is efficacious.
  • a change in the amount of one or more DBMARKERS in the test sample and the reference sample can reflect a less favorable clinical outcome or prognosis.
  • Effective or “effective” means that the treatment leads to an decrease or increase in the amount of one or .
  • DBMARKERS decrease of serum insulin levels or blood glucose levels in a subject.
  • Assessment of serum insulin or blood glucose levels can be analyzed using standard clinical protocols. Efficacy can be determined in association with any known method for diagnosing or treating Diabetes. Levels of an effective amount of DBMARKER proteins, peptides, nucleic acids, polymorphisms, metabolites, or other analytes also allows for the course of treatment of Diabetes or a pre-diabetic condition to be monitored.
  • a biological sample can be provided from a subject undergoing treatment regimens, e.g., drug treatments, for Diabetes.
  • Such treatment regimens can include, but are not limited to, exercise regimens, dietary supplementation (including without limitation, alpha-lipoic acid, chromium, coenzyme QlO, garlic, magnesium, and omega-3 fatty acids), surgical intervention (such as but not limited to gastric bypass, angioplasty, etc.), and treatment with .therapeutics or prophylactics used in subjects diagnosed or identified with Diabetes or a pre-diabetic condition, such as for example, diabetes-modulating agents as defined herein. If desired, biological samples are obtained from the subject at various time points before, during, or after treatment.
  • Levels of an effective amount of DBMARKER proteins, peptides, nucleic acids, polymorphisms, metabolites, or other analytes can then be determined and compared to a reference value, e.g. a control subject or population whose diabetic state is known or an index value or baseline value.
  • the reference sample or index value or baseline value may be taken or derived from one or more subjects who have been exposed to the treatment, or may be taken or derived from one or more subjects who are at low risk of developing Diabetes or a pre-diabetic condition, or may be taken or derived from subjects who have shown improvements in Diabetes risk factors as a result of exposure to treatment.
  • the reference sample or index value or baseline value may be taken or ' derived from one or more subjects who have not been exposed to the treatment.
  • samples may be collected from subjects who have received initial treatment for Diabetes or a pre-diabetic condition and subsequent treatment for Diabetes or a pre-diabetic condition to monitor the progress of the treatment.
  • a reference value can also comprise a value derived from risk prediction algorithms or computed indices from population studies such as those disclosed herein.
  • the DBMARKERS of the present invention can thus be used to generate a "reference expression profile" which comprises a pattern of expression levels of DBMARKERS detected in . those subjects who do not have Diabetes or a pre-diabetic condition such as impaired glucose tolerance, and would not be expected to develop Diabetes or a pre-diabetic condition.
  • the DBMARKERS disclosed herein can also be used to generate a "subject expression profile” comprising a pattern of expression levels of DBMARKERS taken from subjects who have Diabetes or a pre-diabetic condition like impaired glucose tolerance.
  • the subject expression profiles can be compared to a reference expression profile to diagnose or identify subjects at risk for developing Diabetes or a pre-diabetic condition, to monitor the progression of disease, as well as the rate of progression of disease, including development or risk of development of complications related to type 2 Diabetes or pre-diabetic conditions, and to monitor the effectiveness of Diabetes or pre-diabetic condition treatment modalities.
  • the reference and subject expression profiles of the present invention can be contained in a machine-readable medium, such as but not limited to, analog tapes or digital media like those readable by a VCR, CD-ROM, DVD-ROM, USB flash media, among others.
  • Such machine-readable media can also contain additional test ⁇ esults, such as, without limitation, measurements of conventional Diabetes risk factors like systolic and diastolic blood pressure, blood glucose levels, insulin levels, BMI indices, and cholesterol (LDL and HDL) levels.
  • the machine-readable media can also comprise subject information such as medical history and any relevant family history.
  • the machine-readable media can also contain information relating to other Diabetes-risk algorithms and computed indices such as those described herein. Differences in the genetic makeup of subjects can result in differences in their relative abilities to metabolize various agents, which may modulate the symptoms or risk factors of Diabetes or a pre-diabetic condition.
  • Subjects that have Diabetes or a pre-diabetic condition, or at risk for developing Diabetes or a pre-diabetic condition can vary in age, ethnicity, body mass index (BMI), total cholesterol levels, blood glucose levels, blood pressure, LDL and HDL levels, and other parameters. Accordingly, use of the DBMARKERS disclosed herein allow for a predetermined level of predictability that a putative therapeutic or- prophylactic to be tested in a selected subject will be suitable for treating or preventing Diabetes, a pre-diabetic condition, or complications thereof in the subject.
  • BMI body mass index
  • a test sample from the subject can be exposed to a therapeutic agent or a drug, and the level of one or more of DBMARKER proteins, nucleic acids, polymorphisms, metabolites or other analytes can be determined.
  • the level of one or more DBMARKERS can be compared to a sample derived from the subject at a first period of time before and at a second period of time after treatment or exposure to a therapeutic agent or a drug, or can be compared to samples derived from one or . more subjects who have shown improvements in Diabetes or pre-diabetic condition risk factors as a result of such treatment or exposure.
  • Examples of such therapeutics or agents frequently used in Diabetes treatments, and may modulate the symptoms or risk factors of Diabetes include, but are not limited to, sulfonylureas like glimepiride, glyburide (also known in the art as glibenclamide), glipizide, gliclazide; biguanides such as metformin; insulin (including inhaled formulations such as Exubera), and insulin analogs such as insulin lispro (Humalog), insulin glargine (Lantus), insulin detemir, and insulin glulisine; peroxisome proliferator-activated receptor- ⁇ (PPAR- ⁇ ) agonists such as the thiazolidinediones including troglitazone (Rezulin), pioglitazone (Actos), rosiglitazone (Avandia), and isaglitzone (also known as netoglitazone); dual-acting PPAR agonists such as BMS-298585 and
  • Such-therapeuts or agents have been prescribed for subjects diagnosed with Diabetes or a pre-diabetic condition, and may modulate the symptoms or risk factors of Diabetes or a pre-diabetic condition (herein, “diabetes-modulating agents").
  • a subject sample can be incubated in the presence of a candidate agent and the pattern of DBMARKER expression in the test sample is measured and compared to a reference profile, e.g., a Diabetes reference expression profile or a non-Diabetes reference expression profile or an index value or baseline value.
  • the test agent can be any compound or composition or combination thereof.
  • the test agents are agents frequently used in Diabetes treatment regimens and are described herein.
  • Table 1 comprises the one hundred and fifty-eight (158) DBMARKERS of the present invention.
  • DBMARKERS presented herein encompasses all forms and variants, including but not limited to, polymorphisms, isoforms, mutants, derivatives, precursors including nucleic acids, receptors (including soluble and transmembrane receptors), ligands, and post-translationally modified variants, as well as any multi-unit nucleic acid, protein, and glycoprotein structures comprised of any of the DBMARKERS as constituent subunits of the fully assembled structure.
  • Table 1 DBMARKERS
  • DBMARKERS can be determined at the protein or nucleic acid level using any method known in the art.
  • DBMARKER amounts can be detected, inter alia, electrophoretically (such as by agarose gel electrophoresis, sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE), Tris-HCl polyacrylamide gels, non-denaturing protein gels, two-dimensional gel electrophoresis (2DE), and the like), immunochemically (i.e., radioimmunoassay, immunoblotting, immunoprecipitation, immunofluorescence, enzyme-linked immunosorbent assay), by "'proteomics technology", or by "genomic analysis.”
  • electrophoretically such as by agarose gel electrophoresis, sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE), Tris-HCl polyacrylamide gels, non-denaturing protein gels, two-dimensional gel electrophor
  • expression can be measured using reverse- transcription-based PCR assays (RT-PCR), e.g., using primers specific for the differentially expressed sequence of genes.
  • RT-PCR reverse- transcription-based PCR assays
  • Expression can also be determined at the protein level, e.g., by measuring the levels of peptides encoded by the gene products described herein, or activities thereof.
  • Such methods are well known in the art and include, e.g., immunoassays based on antibodies to proteins encoded by the genes, aptamers or molecular imprints.. Any biological material can be used for the detection/quantification of the protein or its activity.
  • a suitable method can be selected to determine the activity of proteins encoded by the marker genes according to the activity of each protein analyzed.
  • Proteomics technology includes, but is not limited to, surface enhanced laser desorption ionization (SELDI), matrix-assisted laser desorption ionization-tirne of flight
  • MALDI-TOF high performance liquid chromatography
  • HPLC high performance liquid chromatography
  • LC/MS liquid chromatography with or without mass spectrometry
  • tandem LC/MS protein arrays, peptide arrays, and antibody arrays.
  • Gene analysis can comprise, for example, polymerase chain reaction (PCR), real- time PCR (such as by Light Cycler®, available from Roche Applied Sciences), serial analysis of gene expression (SAGE), Northern blot analysis, and Southern blot analysis.
  • PCR polymerase chain reaction
  • SAGE serial analysis of gene expression
  • Microarray technology can be used as a tool for analyzing gene or protein expression, comprising a small membrane or solid support (such as but not limited to microscope glass slides, plastic supports, silicon chips or wafers with or without fiber optic detection means, and membranes including nitrocellulose, nylon, or polyvinylidene fluoride).
  • the solid support can be chemically (such as silanes, streptavidin, and numerous other examples) or physically derivatized (for example, photolithography) to enable binding of the analyte of interest, usually nucleic acids, proteins, or metabolites or fragments thereof.
  • the nucleic acid or protein can be printed (i.e., inkjet printing), spotted, or synthesized in situ.
  • Deposition of the nucleic acid or protein of interest can be achieved by xyz robotic microarrayers, which utilize automated spotting devices with very precise movement controls on the X-, y-, and z-axes, in combination with pin technology to provide accurate, reproducible spots on the arrays.
  • the analytes of interest are placed on the solid support in an orderly or fixed arrangement so as to facilitate easy identification of a particularly desired analyte.
  • a number of microarray formats are commercially available from, inter alia, Affymetrix, Arraylt, Agilent Technologies, Asper Biotech, BioMicro, CombiMatrix, GenePix, Nanogen, and Roche Diagnostics.
  • the nucleic acid or protein of interest can be synthesized in the presence of nucleotides or amino acids tagged with one or more detectable labels.
  • labels include, for example, fluorescent dyes and chemiluminescent labels.
  • fluorescent dyes such as but not limited to rhodamine, fluorescein, phycoerythrin, cyanine dyes like Cy3 and Cy5, and conjugates like streptavidin-phycoerythrin (when nucleic acids or proteins are tagged with biotin) are frequently used.
  • Detection of fluorescent signals and image acquisition are typically achieved using confocal fluorescence laser scanning or photomultiplier tube, which provide relative signal intensities and ratios of analyte abundance for the nucleic acids or proteins represented on the array.
  • a wide variety of different scanning instruments are available, and a number of image acquisition and quantification packages are associated with them, which allow for numerical evaluation of combined selection criteria to define optimal scanning conditions, such as median value, interquartile range (IQR), count of saturated spots, and linear regression between pair-wise scans (r 2 and P). Reproducibility of the scans, as well as optimization of scanning conditions, background correction, and normalization, are assessed prior to data analysis.
  • Normalization refers to a collection of processes that are used to adjust data means or variances for effects resulting from systematic non-biological differences between arrays, subarrays (or print-tip groups), and dye-label channels.
  • An array is defined as the entire set of target probes on the chip or solid support.
  • a subarray or print-tip group refers to a subset of . those target probes deposited by the same print-tip, which can be identified as distinct, smaller arrays of proves within the full array.
  • the dye-label channel refers to the fluorescence frequency of the target sample hybridized to the chip.
  • Absolute value methods are used frequently in single-dye experiments or dual-dye experiments where there is no suitable reference for a channel or array.
  • Relevant "hits” are defined as expression levels or amounts that characterize a specific experimental condition. Usually, these are nucleic acids or proteins in which the expression levels differ significantly between different experimental conditions, usually by comparison of the expression levels of a nucleic acid or protein in the different conditions and analyzing the relative expression ("fold change") of the nucleic acid or protein and the ratio of its expression level in one set of samples to its expression in another set. Data obtained from microarray experiments can be analyzed by any one of numerous statistical analyses, such as clustering methods and scoring methods.
  • Clustering methods attempt to identify targets (such as nucleic acids and/or proteins) that behave similarly across a range of conditions or samples. The motivation to find such targets is driven by the assumption that targets that demonstrate similar patterns of expression share common characteristics, such as common regulatory elements, common functions, or common cellular origins.
  • Hierarchical clustering is an agglomerative process in which single-member clusters are fused to bigger and bigger clusters.
  • the procedure begins by computing a pairwise distance matrix between all the target molecules, the distance matrix is explored for the nearest genes, and they are defined as a cluster. After a new cluster is formed by agglomeration of two clusters, the distance matrix is updated to reflect its distance from all other clusters. Then, the procedure searches for the nearest pair of clusters to agglomerate, and so on. This procedure results in a hierarchical dendrogram in which multiple clusters are fused to nodes according to their similarity, resulting in a single hierarchical tree.
  • Hierarchical clustering software algorithms include Cluster and Treeview.
  • X-means clustering is an iterative procedure that searches for clusters that are defined in terms of their "center" points or means. Once a set of cluster centers is defined, each target molecule is assigned to the cluster it is closest to. The clustering algorithm then adjusts the center of each cluster of genes to minimize the sum of distances of target molecules in each cluster to the center. This results in a new choice of cluster centers, and target molecules can be reassigned to clusters. These iterations are applied until convergence is observed.
  • Self- organizing maps (SOMs) are related in part to the £-means procedure, in that the data is assigned to a predetermined set of clusters.
  • Data obtained from high-throughput expression analyses can 4 be scored using statistical methods such as parametric and non-parametric methods.
  • Parametric approaches model expression profiles within a parametric representation and ask how different the parameters of the experimental groups are. Examples of parametric methods include, without limitation, /-tests, separation scores, and Bayesian .-tests.
  • Non-parametric methods involve analysts of the data, wherein no a priori assumptions are made about the distribution of expression profiles in the data, and the degree to which the two groups of expression measurements are distinguished is directly examined. Another method uses the TNOM, or the threshold number of misclassif ⁇ cations, which measures the success in separation two groups of samples by a simple threshold over the expression values.
  • SAGE serial analysis of gene expression
  • SAGE can also be used to systematically determine the levels of gene expression.
  • short sequence tags within a defined position containing sufficient information to uniquely identify a transcript are used, followed by concatenation of tags in a serial fashion. See, for example, Velculescu V.E. et al, (1995) Science 270: 484-487.
  • Polyadenylated RNA is isolated by oligo-dT priming, and cDNA is then synthesized using a biotin-labeled primer.
  • the cDNA is subsequently cleaved with an anchoring restriction endonucleases, and the 3 '-terminal cDNA fragments are bound to streptaviding-coated beads.
  • An oligonucleotide linker containing recognition sites for a tagging enzyme is linked to the bound cDNA.
  • the tagging enzyme can be a class II restriction endonucleases that cleaves the DNA at a constant number of bases 3' to the recognition site, resulting in the release of a short tag and the linker from the beads after digestion with the en ⁇ yme.
  • the 3' ends of the released tags plus linkers are then blunt-ended and ligated to one another to form linked ditags that are approximately 100 base pairs in length.
  • the ditags are then subjected to PCR amplification, after which the linkers and tags are released by digestion with the anchoring restriction endonucleases.
  • the tags (usually ranging in size from 25-30-mers) are gel purified, concatenated, and.cloned into a sequence vector. Sequencing the concatemers enables individual tags to be identified and the abundance of the transcripts for a given cell or tissue type can be determined.
  • the DBMARKER proteins, polypeptides, mutations, and polymorphisms thereof can be detected in any manner known to those skilled in the art.
  • two-dimensional gel electrophoresis which separates a mixture of proteins (such as found in biological samples such as serum) in one dimension according to the isoelectric point (such as, for example, a pH range from 5-8), and according .to molecular weight in a second dimension.
  • Two-dimensional liquid chromatography is also advantageously used to identify or detect DBMARKER proteins, polypeptides, mutations, and polymorphisms of the invention, and one specific example, the ProteomeLab PF 2D Protein Fractionation System is detailed in the Examples.
  • the PF 2D system resolves proteins in one dimension by isoelectric point and by hydrophobicity in the second dimension.
  • Another advantageous method of detecting proteins, polypeptides, mutations, and polymorphisms include SELDI (disclosed herein) and other high- throughput proteomic arrays.
  • DBMARKER proteins, polypeptides, mutations, and polymorphisms can be typically detected by contacting a sample from the subject with an antibody which binds the DBMARKER protein, polypeptide, mutation, or polymorphism and then detecting the presence or absence of a reaction product.
  • the antibody may be monoclonal, polyclonal, chimeric, or a fragment of the foregoing, as discussed in detail above, and the step of detecting the reaction product may be carried out with any suitable immunoassay.
  • the sample from the subject is typically a biological fluid as described above, and may be the same sample of biological fluid used to conduct the method- described above. :
  • Immunoassays carried out in accordance with the present invention may be homogeneous assays or heterogeneous assays.
  • the immunological reaction usually involves the specific antibody (e.g., anti-DBMARKER protein antibody), a labeled analyte, and the sample of interest.
  • the signal arising from the label is modified, directly or indirectly, upon the binding of the antibody to the labeled analyte.
  • Both the immunological reaction and detection of the extent thereof can be carried out in a homogeneous solution.
  • Immunochemical labels which may be employed include free radicals, radioisotopes, fluorescent dyes, enzymes, bacteriophages, or coenzymes.
  • the reagents are usually the sample, the antibody, and means for producing a detectable signal.
  • Samples as described above may be used.
  • the antibody can be immobilized on a support, such as a bead (such as protein A agarose, protein G agarose, latex, polystyrene, magnetic or paramagnetic beads), plate or slide, and contacted with the specimen suspected of containing the antigen in a liquid phase.
  • the support is then separated from the liquid phase and either the support phase or the liquid phase is examined for a detectable signal employing means for producing such signal.
  • the signal is related to the presence of the analyte in the sample.
  • Means for producing a detectable signal include the use of radioactive labels, fluorescent labels, or enzyme labels.
  • an antibody which binds to that site can be conjugated to a detectable group and added to the liquid phase reaction solution before the separation step.
  • the presence of the detectable group on the solid support indicates the presence of the antigen in the test sample.
  • suitable immunoassays are oligonucleotides, immunoblotting, immunoprecipitation, immunofluorescence methods, chemiluminescence methods, electrochernilurninescence or enzyme-linked immunoassays.
  • Antibodies can be conjugated to- a solid support suitable for a diagnostic assay (e.g., beads such as protein A or protein G agarose, microspheres, plates, slides or wells formed from materials such as latex or polystyrene) in accordance with known techniques, such as passive binding.
  • a diagnostic assay e.g., beads such as protein A or protein G agarose, microspheres, plates, slides or wells formed from materials such as latex or polystyrene
  • Antibodies as described herein may likewise be conjugated to detectable labels or groups such as radiolabels (e.g., 35 S, 125 1, 131 I), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescent labels (e.g., fluorescein, Alexa, green fluorescent protein) in accordance with known techniques.
  • radiolabels e.g., 35 S, 125 1, 131 I
  • enzyme labels e.g., horseradish peroxidase, alkaline phosphatase
  • fluorescent labels e.g., fluorescein, Alexa, green fluorescent protein
  • Antibodies can also be useful for detecting post-translational modifications of DBMARKER proteins, polypeptides, mutations, and polymorphisms, such as tyrosine phosphorylation, threonine phosphorylation, serine phosphorylation, glycosylation (e.g., O- GIcNAc).
  • Such antibodies specifically detect the phosphorylated amino acids in a protein or proteins of interest, and can be used in immunoblotting, immunofluorescence, and ELISA assays described herein. These antibodies are well-known to those skilled' in the art, and commercially available.
  • Post-translational modifications can also be determined using metastable ions in reflector matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI- TOF) (Wirth, U. et al. (2002) Proteomics 2(10): 1445-51).
  • MALDI- TOF reflector matrix-assisted laser desorption ionization-time of flight mass spectrometry
  • DBMARKER proteins, polypeptides, mutations, and polymorphisms known to have enzymatic activity the activities can be determined in vitro using enzyme assays known in the art.
  • enzyme assays include, without limitation, kinase assays, phosphatase assays, reductase assays, among many others.
  • Modulation of me kinetics of enzyme activities can be determined by measuring the rate constant K M using known algorithms, such as the Hill plot, Michaelis-Menten equation, linear regression plots such as Lineweaver-Burk analysis, and Scatchard plot.
  • sequence information provided by the database entries for the DBMARKER sequences expression of the DBMARKER sequences can be detected (if present) and measured using techniques well known to one of ordinary skill in the art.
  • sequences within the sequence database entries corresponding to DBMARKER sequences, or within the sequences disclosed herein can be used to construct probes for detecting DBMARKER RNA sequences in, e.g., Northern blot hybridization analyses or methods which specifically, and, preferably, quantitatively amplify specific nucleic acid sequences.
  • sequences can be used to construct primers for specifically amplifying the DBMARKER sequences in, e.g., amplification-based detection methods such as reverse-transcription based polymerase chain reaction (RT-PCR).
  • amplification-based detection methods such as reverse-transcription based polymerase chain reaction (RT-PCR).
  • RT-PCR reverse-transcription based polymerase chain reaction
  • sequence comparisons in test and reference populations can be made by comparing relative amounts of the examined DNA sequences in the test and reference cell populations.
  • RNA level expression of the genes disclosed herein can be measured at the RNA level using any method known in the art. For example, Northern hybridization analysis using probes which . specifically recognize one or more of these sequences can be used to determine gene expression. Alternatively, expression can be measured using reverse-transcription-based PCR assays (RT- PCR), e.g., using primers specific for the differentially expressed sequences.
  • RT- PCR reverse-transcription-based PCR assays
  • DBMARKER protein and nucleic acid metabolites or fragments can be measured.
  • the term "metabolite” includes any chemical or biochemical product of a metabolic process, such as any compound produced by the processing, cleavage or consumption of a biological molecule (e.g., a protein, nucleic acid, carbohydrate, or lipid).
  • Metabolites can be detected in a variety of ways known to one of skill in the art, including the refractive index , spectroscopy (RI), ultra-violet spectroscopy (UV), fluorescence analysis, radiochemical analysis, near-infrared spectroscopy (near-IR), nuclear magnetic resonance spectroscopy (NMR), light scattering analysis (LS), mass spectrometry, pyrolysis mass spectrometry, nephelometry, dispersive Raman spectroscopy, gas chromatography combined with mass spectrometry, liquid chromatography combined with mass spectrometry, matrix-assisted laser desorption ionization- time of flight (MALDI-TOF) combined with mass spectrometry, surface-enhanced laser desorption ionization (SELDI), ion spray spectroscopy combined with mass spectrometry, capillary electrophoresis, NMR and IR detection.
  • RI spectroscopy
  • UV ultra-violet spectroscopy
  • the invention also includes a DBMARKER-detection reagent, e.g., nucleic acids that specifically identify one or more DBMARKER nucleic acids by having homologous nucleic acid sequences, such as oligonucleotide sequences, complementary to a portion of the DBMARKER nucleic acids or antibodies to proteins encoded by the DBMARKER nucleic acids packaged together in the form of a kit.
  • a DBMARKER-detection reagent e.g., nucleic acids that specifically identify one or more DBMARKER nucleic acids by having homologous nucleic acid sequences, such as oligonucleotide sequences, complementary to a portion of the DBMARKER nucleic acids or antibodies to proteins encoded by the DBMARKER nucleic acids packaged together in the form of a kit.
  • the oligonucleotides can be fragments of the DBMARKER genes.
  • the oligonucleotides can be 200, 150
  • the DBMARKER-detection reagents can also comprise, inter alia, antibodies or fragments of antibodies, and aptamers.
  • the kit may contain in separate containers a nucleic acid or antibody (either already bound to a solid matrix or packaged separately with reagents for binding them to the matrix), control formulations (positive and/or negative), and/or a detectable label. Instructions (e.g., written, tape, VCR, CD-ROM, etc.) for carrying out the assay may be included in the kit.
  • the assay may for example be in the form of a Northern blot hybridization or a sandwich ELISA as known in the art.
  • the kit can be in the form of a microarray as known in the art.
  • kits of the present invention comprise a control (or reference) sample derived from a subject having normal glucose levels.
  • the kits can comprise a control sample derived from a subject who has been diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.
  • the diagnostic kit comprises (a) an antibody (e.g., fibrinogen ⁇ C domain peptide) conjugated to a solid support and (b) a second antibody of the invention conjugated to a detectable group.
  • the reagents may also include ancillary agents such as- buffering agents and protein stabilizing agents, e.g., polysaccharides and the like.
  • the diagnostic kit may further include, where necessary, other members of the signal-producing system of which system the detectable group is a member (e.g., enzyme substrates), agents for reducing background interference in a test, control reagents, " apparatus for conducting a test, and the like.
  • a test kit contains (a) an antibody , and (b) a specific binding partner for the antibody conjugated to a detectable group.
  • the test kit may be packaged in any suitable manner, typically with all elements in a single container, optionally with a sheet of printed instructions for carrying out the test.
  • DBMARKER detection reagents can be immobilized on a solid matrix such as a porous strip to form at least one DBMARKER detection site.
  • the measurement or detection region of the porous strip may include a plurality of sites containing a nucleic acid.
  • a test strip may also contain sites for negative and/or positive controls. Alternatively, control sites can be located on a separate strip from the test strip.
  • the different detection sites may contain different amounts of immobilized nucleic acids, e.g., a higher amount in the first detection site and lesser amounts in subsequent sites.
  • the number of sites displaying a detectable signal provides a quantitative indication of the amount of DBMARKERS present in the sample.
  • the detection sites may be configured in any suitably detectable shape and are typically in the shape of a bar or dot spanning the width of a test strip.
  • the kit contains a nucleic acid substrate array comprising one or more nucleic acid sequences.
  • the nucleic acids on the array specifically identify one or more nucleic acid sequences represented by DBMARKERS 1-158.
  • the expression of 2, 3,4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, or more of the DBMARKERS 1-158 can be identified by virtue of binding to the array.
  • the substrate array can be on, e.g., a solid substrate, e.g., a "chip" as described in U.S. Patent No.5,744,305.
  • the substrate array can be a solution array, e.g., xMAP (Luminex, Austin, TX), Cyvera (Illumina, San Diego, CA), CellCard (Vitra Bioscience, Mountain View, CA) and Quantum Dots' Mosaic (Invitrogen, Carlsbad, CA).
  • xMAP Luminex, Austin, TX
  • Cyvera Illumina, San Diego, CA
  • CellCard Vitra Bioscience, Mountain View, CA
  • Quantum Dots' Mosaic Invitrogen, Carlsbad, CA.
  • nucleic acid probes e.g., oligonucleotides, aptamers, siRNAs, antisense oligonucleotides, against any of the DBMARKERS in -Table 1.
  • the Examples presented herein describe generation of monoclonal antibodies in mice, v as well as generation of polyclonal hyperimmune serum from rabbits. Such techniques are well-known to those of ordinary skill in the art.
  • treating in its various grammatical forms in relation to the present invention refers to preventing (i.e. chemoprevention), curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression, disease causative agent (e.g., bacteria or viruses) or other abnormal condition.
  • treatment may involve alleviating a symptom (i.e., not necessarily all symptoms) of a disease or attenuating the progression of a disease.
  • the term "therapeutically effective amount” is intended to qualify the amount or amounts of DBMARKERS or other diabetes-modulating agents that will achieve a desired biological response.
  • the desired biological response can be partial or total inhibition, delay or prevention of the progression of type 2 Diabetes, pre-diabetic conditions, and complications associated with type 2 Diabetes or pre- diabetic conditions; inhibition, delay or prevention of the recurrence of type 2 Diabetes, pre- diabetic conditions, or complications associated with type 2 Diabetes or pre-diabetic conditions; or the prevention of the onset or development of type 2 Diabetes, pre-diabetic conditions, or complications associated with type 2 Diabetes or pre-diabetic conditions (chemoprevention) in a subject, for example a human.
  • the DBMA-R-KERS 3 preferably included as part of a pharmaceutical composition, can be administered by any known administration method known to a person skilled in the art.
  • routes of administration include but are not limited to oral, parenteral, intraperitoneal, intravenous, intraarterial, transdermal, topical, sublingual, intramuscular, rectal, transbuccal, intranasal, liposomal, via inhalation, vaginal, intraoccular, via local delivery by catheter or stent, subcutaneous, intraadiposal, intraarticular, intrathecal, or in a slow release dosage form.
  • the DBMAR-KERS or pharmaceutical compositions comprising the DBMARKERS can be administered in accordance with any dose and dosing schedule that achieves a dose effective to treat disease.
  • DBMARKERS or pharmaceutical compositions comprising DBMARKERS of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
  • the DBMARKERS or pharmaceutical compositions comprising DBMARKERS can be administered by intravenous (e.g., bolus or infusion), intraperitoneal, subcutaneous, intramuscular, or other routes using forms well known to those of ordinary skill in the pharmaceutical arts.
  • DBMARKERS and pharmaceutical compositions comprising DBMARKERS can also be administered in the form of a depot injection or implant preparation, which may be formulated in such a manner as to permit a sustained release of the active ingredient.
  • the active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants.
  • Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.
  • DBMARKERS or pharmaceutical compositions comprising DBMARKERS can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines. Liposomal preparations of diabetes-modulating agents may also be used in the methods of the invention.
  • DBMARKERS or pharmaceutical compositions comprising DBMARKERS can also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • DBMARKERS or pharmaceutical compositions comprising DBMARKERS can also be prepared with soluble polymers as targetable drug carriers.
  • soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylarnide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • DBMARKERS or pharmaceutical compositions comprising DBMARKERS can be prepared with biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • DBMARKERS or pharmaceutical compositions comprising DBMARKERS can also be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime.
  • Suitable pharmaceutically acceptable salts of the agents described herein and suitable for use in the method of the invention are conventional non-toxic salts and can include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., lithium salt, sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.) etc.; an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate,
  • this invention also encompasses pharmaceutical compositions comprising any solid or liquid physical form of one or more of the DBMARKERS of the invention.
  • the DBMARKERS can be in a crystalline form, in amorphous form, and have any particle size.
  • the DBMARKER particles may be micronized, or may be agglomerated, particulate granules, powders, oils, oily suspensions or any other form of solid or liquid physical form.
  • the pharmaceutical compositions can be liquid or solid. Suitable solid oral formulations include tablets, capsules, pills, granules, pellets, and the like. Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils, and the like.
  • compositions of the present invention may be used in the formulations of the present invention, such as for example, a gum, a starch, a sugar, a cellulosic material, an acrylate, or mixtures thereof.
  • the compositions may further comprise a disintegrating agent and a lubricant, and in addition may comprise one or more additives selected from a binder, a buffer, a protease inhibitor, a surfactant, a solubilizing agent, a plasticizer, an emulsifier, a stabilizing agent, a viscosity increasing agent, a sweetener, a film forming agent, or any combination thereof.
  • the compositions of the present invention may be in the form of controlled release or immediate release formulations.
  • DBMARKERS can be administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as “carrier” materials or “pharmaceutically acceptable carriers”) suitably selected with respect to the intended form of administration.
  • carrier materials or “pharmaceutically acceptable carriers”
  • pharmaceutically acceptable carrier or diluent is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference.
  • pharmaceutically acceptable carriers may be aqueous or nonaqueous solutions, suspensions, emulsions or oils.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions, or suspensions, including saline and buffered media.
  • oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.
  • Solutions or suspensions can also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • Liposomes and non-aqueous vehicles such as fixed oils may also be used.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • Solid carriers/diluents include, but are not limited to, a gum, a starch (e.g., corn starch, pregelatinized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g., microcrystalline cellulose), an acrylate (e.g., polymethylacrylate), calcium carbonate- magnesium oxide, talc, or mixtures thereof.
  • a gum e.g., corn starch, pregelatinized starch
  • a sugar e.g., lactose, mannitol, sucrose, dextrose
  • a cellulosic material e.g., microcrystalline cellulose
  • an acrylate e.g., polymethylacrylate
  • calcium carbonate- magnesium oxide talc, or mixtures thereof.
  • compositions may further comprise binders (e.g., acacia, cornstarch, • gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarmellose sodium, crospovidone, guar guiri s sodium starch glycolate, Primogel), buffers (e.g., tris-HCl, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic ⁇ 68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol,
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • the pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • compositions that contain an active component are well understood in the art, for example, by mixing, granulating, or tablet-forming processes.
  • the active therapeutic ingredient is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient.
  • the active agents are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic, or oily solutions and the like as detailed above.
  • Glucuronic acid L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration can be used as buffers.
  • Sodium chloride solution wherein the pH has been adjusted to the desired range with either acid or base, for example, hydrochloric acid or sodium hydroxide, can also be employed.
  • a pH range for the intravenous formulation can be in the range of from about 5 to about 12.
  • a particular pH range for intravenous formulation comprising an HDAC inhibitor, wherein the HDAC inhibitor has a hydroxamic acid moiety can be about 9 to about 12.
  • Subcutaneous formulations can be prepared according to procedures well known in the art at a pH in the range between about 5 and about 12, which include suitable buffers and isotonicity agents. They can be formulated to deliver a daily dose of the active agent in one or more daily subcutaneous administrations.
  • suitable buffers and isotonicity agents include suitable buffers and isotonicity agents. They can be formulated to deliver a daily dose of the active agent in one or more daily subcutaneous administrations.
  • the choice of appropriate buffer and pH of a formulation, depending on solubility of one or more DBMARKERS to be administered, is
  • Sodium chloride solution wherein the pH has been adjusted to the desired range with either acid or base, for example, hydrochloric acid or sodium hydroxide, can also be employed in the subcutaneous formulation.
  • a pH range for the subcutaneous formulation can be in the range of from about 5 to about 12.
  • compositions of the present invention can also be administered in intranasal form via
  • Example 1 Biomarker Identification in the Cohen rat model of Type 2 Diabetes
  • the Cohen diabetic (CD) rat is a well-known and versatile animal model of Type 2 Diabetes, and is comprised of 2 rodent strains that manifest many of the common features of Type 2 Diabetes (T2D) in humans.
  • the sensitive strain (CDs) develops Diabetes within 30 days 25 when maintained on a high sucrose/copper-poor diet (HSD), whereas the resistant strain (CDr) retains normal blood glucose levels.
  • HSD high sucrose/copper-poor diet
  • RD regular rodent diet
  • Serum, urine, and tissue samples were obtained from both CDr and CDs rats that were fed either RD or HSD for 30 days. The samples were flash-frozen and stored at -80 0 C. .
  • Whole protein extracts were prepared for each of the 4 experimental conditions, utilizing 10 individual organs per group. Pancreatic tissues were processing using a mechanical shearing device (Polytron). To preserve protein integrity in processed samples, tissues were kept on dry ice until processing commenced and all buffers and equipment were pre-chilled. Samples were also kept on ice during the homogenization process.
  • T-Per buffer (Pierce) was pre-chilled on ice and two tablets of Complete Protease Inhibitor (Roche Applied Sciences) were added per 50 ml of buffer prior to use. Once protease inhibitors, were added, any unused buffer was discarded. T-Per buffer was used at 20 ml per gram of tissue. For each group, pancreatic samples were weighed and the amount of lysis buffer required was calculated and added to each tissue sample in a 50 ml tube. Each sample was homogenized on ice for 10 seconds, followed by a 30 second rest period to allow the sample to cool. If gross debris was still apparent, the cycle was repeated until the homogenate was smooth. The hornogenization probe was inserted into the samples approximately 1 cm from the bottom of the tube to minimize foaming. When homogenization was complete, the extract was centrifuged at 10,000 x g for 15 minutes at 4°C. .
  • Table 2 provides the mean protein content of the samples corresponding to CDr rats fed either RD or HSD, and CDs rats fed either RD or HSD.
  • albumin, immunoglobulin and other abundant proteins constitute about 95-97% of the total proteins in serum, the detection of less abundant proteins and peptides markers are masked if the whole serum were analyzed directly. Therefore, fractionation of serum samples was necessary to reduce masking of low abundance protein and to increase the number of peaks available for analysis.
  • the crude serum samples from CDr and CDs rats fed RD or HSD were fractionated into six fractions.
  • the fractionation was carried out using anion exchange bead based serum fractionate kit purchased from Ciphergen (Fremont, CA).
  • the serum samples were diluted with a 9M urea denaturant>solution; the diluted samples were then loaded onto a 96-well filter microplate pre-filled with an anion exchange sorbent.
  • samples were allowed to bind to the active surface of the beads, and after 30 minutes incubation at 4°C, the samples were eluted using stepwise pH gradient buffers.
  • the process allowed the collection of 6 fractions including pH 9, pH 7, pH 5, pH 4, pH 3 and an organic eluent. After the fractionation, the serum samples were analyzed in the following formats on SELDI chips.
  • SELDI Surface Enhanced Laser Desorption Ionization
  • SELDI Proteinchip ® Technology (Ciphergen) is designed to perform mass spectrometric analysis of protein mixtures retained on chromatographic chip surfaces.
  • the SELDI mass spectrometer produces spectra of complex protein mixtures based on the mass/charge ratio of the proteins in the mixture and their binding affinity to the chip surface. Differentially expressed proteins are determined from these protein profiles by comparing peak intensity.
  • This technique utilizes aluminum-based supports, or chips, engineered with chemical modified surfaces (hydrophilic, hydrophobic, pre-activated, normal-phase, immobilized metal affinity, cationic or anionic), or biological (antibody, antigen binding fragments (e.g.,- scFv), DNA, enzyme, or . receptor) bait surfaces.
  • fractionated serum samples were applied to different chemically modified surface chips (cationic exchange, anionic exchange, metal-affinity binding, hydrophobic and normal phase) and profiled by SELDI, two-dimensional PAGE (2DE) and two-dimensional liquid chromatography (2D/LC).
  • the ProteomeLab PF 2D Protein Fractionation System is a fully automated, two- dimensional fractionation system (in liquid phase) that resolves and collects proteins by isoelectric point (pi) in the first dimension and by hydrophobicity in the second dimension.
  • the system visualizes the complex pattern with a two dimensional protein map that allows the direct comparison of protein profiling between different samples. Since all components are isolated and collected in liquid phase, it is ideal for downstream protein identification using mass spectrometry and/or protein extraction for antibody production.
  • the PF 2D system addresses many of the problems associated with traditional proteomics research, such as detection of low abundance proteins, run-to-run reproducibility, quantitation, detection of membrane or hydrophobic proteins, detection of basic proteins and detection of very low and very high molecular weight proteins.
  • the serum samples were partitioned using IgY-R7 rodent optimized partition column to separate the seven abundant proteins (Albumin, IgG, Transferrin, Fibrinogen, IgM, ⁇ l -Antitrypsin, Haptoglobin) from the, less abundant ones.
  • the partitioned serum was applied to the PF-2D.
  • the first dimensional chromatofocusing was performed on an HPCF column with a linear pH gradient generated using start buffer (pH 8.5) and eluent buffer (pH 4.0).
  • the proteins were separated based on the pi. Fractions were collected and applied.to a reverse-phase HPRP column for a second dimensional separation. The 2D map generated from each sample was then compared and differential peak patterns were identified. The fraction was subsequently selected and subjected to trypsin digestion. The digested samples were sequenced using LC/MS for protein identification.
  • Two-dimensional electrophoresis has the ability to resolve complex mixtures of thousands of proteins simultaneously in a single gel. In the first dimension, proteins are separated by pi, while in the second dimension, proteins are separated by MW. Applications of 2D gel electrophoresis include proteome analysis, cell differentiation, detection of disease markers, monitoring response to treatment etc.
  • IgY partitioned serum samples were applied to immobilized pH gradient (IPG) strips with different pH gradients, pH 3-10,-pH 3-6 and pH 5-8. After the first dimensional run, the IPG strip was laid on top of an 8-16% or 4-20% SDS-PAGE gradient gel for second dimensional separation.
  • IPG immobilized pH gradient
  • FIG. 2A A peak protein of approximately 4200 daltons was present in the serum of CDr-RD and CDr-HSD, but not in the serum of CDs-RD or CDs-HSD, as shown in Figure 2A.
  • Figure 2B is a MS/MS spectrum of the 4200 dalton fragment.
  • This protein was sequenced and following extensive database searches, was found to be a novel protein.
  • the peptide was designed "D3" and its sequence was found to be SGRPP MTVWF NRPFL IAVSH THGQT ILFMA KVINP VGA (SEQ ID NO: 1).
  • the D3 peptide is a 38-mer peptide sequence that corresponds to the first biomarker discovered in the Cohen diabetic rat.
  • RT-PCR reverse-transcription polymerase chain reactions
  • Table 3 represents additional identified candidate markers identified by SELDI analysis.
  • Figures 4 A and 4B represent gels depicting biomarkers identified by LC/MS technology and a graph showing an elution profile obtained by differential two-dimensional reverse-phase HPLC or CDr-RD (red) versus CDs-RD (green) of a selected first dimension pi fraction (fraction 31).
  • Figure 5 A represent 2DE gels of samples derived from each of the four Cohen diabetic rat models
  • Figure 5B is a magnified view of spots identified in Figure 4A identified as apolipoprotem E, liver regeneration-related protein, and a previously unidentified protein.
  • Figure 6 is a graphical representation illustrating the differentially expressed proteins found in the four Cohen Diabetic rat models using 2DE technology.
  • Figure 7 is a histogram showing the differentially expressed Cohen Diabetic rat serum proteins identified by 2DE.
  • FIG. 8 depicts Western blots showing the reactivity of the D3 hyper-immune serum with a ⁇ 4 kD protein isolated from CDr-RD and CDr-HSD rat serum fraction 6. Fractionated CD rat serum samples were run on a 10% SDS-PAGE gel, then transferred to PVDF membranes. A higher molecular weight doublet (in the range of 49 and 62 kD) also reacted with the hyper-immune sera, indicated that a parent protein is expressed by all strains under treatment modalities RD or HSD, however a derivative of smaller size (-4 kD) corresponding to the D3 fragment is differentially expressed only in the CDr strain.
  • the concentration of the D3 fragment in CDr rat serum was subsequently analyzed by SELDI.
  • a series of synthetic D3 peptide standards (0.1, 0.033, 0.011, 0.0037, 0.0012 and 0 mg/ml) and 1OX diluted CDr-serum were spotted in duplicate on QlO protein chip arrays.
  • the peak intensity was plotted against the concentration of D3 peptide standards. Based on the plot ( Figure 9), the linear range for concentration determination is from 0 to 0.01 mg/ml. Accordingly, the concentration of D3 in CDr-RD serum is around 0.04 mg/ml, based on the peak intensity of the CDr-RD serum sample.
  • Table 4 contains a summary of biomarker data obtained from CD rat serum samples.
  • D3 hyper immune serum (rabbit; Figure 11).
  • the primary antibody used was rabbit polyclonal antibodies produced following immunization with D3 peptide.
  • a protein with molecular weight of 20 kD (between the 14 kD and 28 kD markers) is expressed in human serum at a higher intensity in the normal individual as compared with Type 2 diabetic patient.
  • a pair of proteins with MW of 60-80 kD appear to be present in both (normal and diabetic) samples.
  • the intensity of the proteins in the doublet seemed to be inverted; an observation that was made using monoclonal antibodies derived from a sub tractive immunization with CDr-HSD and CDs-HSD pancreas.
  • Figures 12A and 12B show preparative gels containing 100 ⁇ g of CDr-HSD or 'CDs-HSD pancreatic extracts.
  • the positive control was stained with 20 ⁇ g of anti-actin antibodies, and subclone lanes were stained with 600 ⁇ l of conditioned culture supernatant (described elsewhere in this disclosure).
  • FIG. 14 depicts apseudogel view of SELDI analysis of Fraction 1 of the samples. Each lane represents a spectrum of an individual sample from M/Z 14.0 kD to 16.0 kD. The M/Z for the protein bands are approximately 15.2, 14.8, and 14.5 kD, respectively.
  • Figure 15 is another pseudogel view of SELDI analysis performed on 13 T2D and 16 normal fractionated serum samples (Fraction 3), profiled on a QlO protein chip. Each lane represents the spectrum of an individual sample from M/Z 8.0 kD to 10.0 kD. The M/Z for the protein marker is approximately 9.3 kD.
  • the graph below in Figure 15 is a cluster view of a marker (M/Z -6430) that is downregulated in T2D samples. Levels of albumin were profiled using SELDI on the Cheatham samples and were compared to the Dankner samples, as shown in Figure 16.
  • Example 3 Bi-Directional Immunological Contrasting and Generation of Monoclonal Antibodies From the pancreatic extract protein profiles obtained by SDS-PAGE, obvious differences in the banding patterns were noted between CDr-HSD and CDs-HSD samples ( Figure 1). Bidirectional immunological contrast was performed between these two samples.
  • This technique involves injecting two pancreatic extracts from the Cohen diabetic rats to be contrasted separately into the footpads of an experimental animal (e.g. a Balb/c mouse). Following uptake and processing of the antigen at the site of injection by antigen presenting cells (APCs), the activated APCs'migrate to the local lymph nodes (popliteal) to initiate an immune response.
  • APCs antigen presenting cells
  • lymph nodes As these lymph nodes are located in each leg, they are anatomically separated from each other, which prevents mixing of antigen-specific lymphocytes at this point. Later in the immune response, these activated lymphocytes migrate from the local lymph nodes to the spleen where they become mixed, and from where they may circulate systemically.
  • Ribi adjuvant was warmed to 37 0 C and reconstituted with 1 ml of sterile PBS. The bottle was vortexed for at least 1 minute to fully reconstitute the material. The correct volume of Ribi adjuvant was then added to the antigen preparation, and the mixture was again vortexed for 1 minute. Any unused formulated material was discarded, and any unused Ribi adjuvant was stored at 4°C and used to formulate booster injections. Animals were primed on day 1 and boosted on day 14. Animals were euthanized on day 17, when popliteal lymph nodes were excised post mortem and returned to the lab for processing.
  • Hybridomas Hybridoma cell lines were created essentially as described by Kohler and Milstein (1975).
  • Lymphocytes derived from immunized animals were fused with a murine myeloma cell line (Sp2/0) by incubation with polyethylene glycol (PEG). Following fusion, cells were maintained ⁇ - in selective medium containing hypoxanthine, aminopterin and thymidine (HAT medium) that facilitates only the outgrowth of chimeric fused cells.
  • the fusion partner Sp2/0x Agl4 cells in dividing stage with viability above 95%) was split at l ⁇ 10 5 viable cells/ml, 24 hours before the fusion.
  • mice On the day of the fusion, the mice were sacrificed and the lymph nodes were excised and placed in a Petri dish containing pre-warmed room temperature DMEM supplemented with 10% fetal bovine serum (FBS). Using sterile microscope slides, the lymph nodes were placed between the 2 frosty sides of the slides and crushed into a single cell suspension. The cell suspension was then transferred to a 15 ml tube and centrifuged for 1 minute at 1000 rpm. The supernatant was removed by aspiration, and the cell pellet gently resuspended in 12 ml of serum-free DMEM, after which they were subjected to another round of centrifugation for 10 minutes at 1000 rpm. The process was repeated twice more to ensure that the serum was completely removed. After washing, the cells were resuspended in 5 ml of serum-free DMEM and counted under the microscope.
  • FBS fetal bovine serum
  • the fusion partner was collected by spinning in a centrifuge for 10 minutes at 1000 rpm. The cells were washed three times in serum-free DMEM, and finally resuspended in serum-free DMEM and counted. The number of fusion partner cells were calculated based on the number of lymph node cells. For every myeloma cell (fusion partner), 2 lymph nodes cells is needed (ratio 1:2 of myeloma to lymph node cells; e.g. for 1OxIO 6 lymph node cells, 5xlO 6 fusion partner cells are needed).
  • the appropriate number of myeloma cells to the LN cells were added and the total volume of cells was adjusted to 25 ml using serum free DMEM, and 25 ml of 3% dextran was then added to the cells. The mixture was spun for 10 minutes at 1000 rpm, and the supernatant aspirated as much as possible from the cell pellet. Once the Hd was placed onto the tube containing the cells, the bottom of the tube was gently tapped the bottom of the tube to resuspend the cells and 1 ml of pre- warmed 50% (v/v) PEG was added to the tube.
  • the agglutinated cells were allowed to sit for 1 minute, after which 20 ml of serum free DMEM, followed by 25 ml of 20% FBS, DMEM with 25 mM Hepes was added. The tube was inverted once to mix and then centrifuged for 10 minutes at 1000 rpm. The media was aspirated and the cells were gently resuspended by tapping. HAT selection media was added such that the cell suspension was either at 0.125 x 10 6 cells/ml or 0.0625 * 10 6 cells/ml. One hundred ⁇ l of cells per well were added to a 96-well flat bottom plate and incubated at 37°C with CO 2 at 8.5%. After 2 days, the cells were fed with 100 ⁇ l of fresh HAT selection media. Cells were checked for colony growth after 7 days.
  • Pancreas extract at a concentration of 25 ⁇ g/ml to be tested was diluted in carbonate bicarbonate buffer (1 capsule of carbonate-bicarbonate was dissolved in 100 ml of deionized water). Two extra wells for the positive control and two extra wells for the negative control of a 96-well plate were reserved. The plate was then covered using adhesive film and incubated at 4°C overnight.
  • the plate was washed once with 200 ⁇ l of PBS/Tween. The well content was removed by flicking the plate into a sink, and then gently tapping the plate against absorbent paper to remove remaining liquid. Approximately 200 ⁇ l of washing buffer (PBS/Tween) was added and subsequently discarded as previously described. The entire plate was then blocked for 1 hour at 37°C in 200 ⁇ l of 5% powdered milk/PBS/Tween. The plate was then washed 3 times using PBS/Tween as previously described.
  • the fusion culture supernatant was diluted 1:1 in 0.5% milk/PBS/Tween and each sample added to the wells (50 ⁇ l; final volume is 100 ⁇ l per well) with 50 ⁇ l of anti-actin Ab (Sigma) at 20 ⁇ g/ml to well containing 50 ⁇ l of buffer. Fifty ⁇ l of buffer was added to the negative control well. The plate was covered and incubated overnight at 4°C. The plate was was washed 3 times using PBS/Tween as previously described, and anti-HRP anti-mouse IgG in 0.5% milk/PBS/Tween at 1 -.20000 (lOO ⁇ l) was added to each well. The plate was covered and incubated at 37°C for two hours.
  • each colony was subcloned by limiting dilution.
  • the resulting clonal lines derived from each parent colony were rescreened and ranked by O.D. 450 nm to determine the best clones.
  • the top 10 antibody secreting clones were expanded and archived in liquid nitrogen storage. Cells were counted and ensured that the viability was at least 80%.
  • Cells were prepared in subcloning media containing 10% FBS and 10% hybridoma cloning factor (bioVeris) in DlVBEM at 5 cells/ml (about 60 ml for 3 plates). Another set of the same cells was prepared at a concentration of ⁇ 1.6 cells/ml (about 60 ml for 3 plates).
  • composition of each mAb was defined by determining the class of heavy and light chains, as well as the molecular weight, of each component. Isotyping was performed using the Immunopure monoclonal antibody isotyping kit I (Pierce) according to the manufacturer's instructions. The molecular weight of heavy and light chains was determined using the Experion automated electrophoresis system from Bio-Rad. The Experion system automatically performs the multiple steps of gel-based electrophoresis: separation, staining, destaining, band detection, imaging, and data analysis. The results of these analyses are shown in Table 9, which shows the physical characterization of CDr-HSD and CDs-HSD specific monoclonal antibodies.
  • each mAb was tested by Western Blotting to ascertain the molecular weight of the corresponding antigen. Data obtained from reactive clones is shown in Figures 18A-18 C. To purify the antigen specific for P2-10-B8-KA8, an immunoprecipitation was performed.
  • Protein G beads slurry (1 ml) were centrifuged for 3 minutes at 500 x g in an Eppendorf centrifuge, and washed twice with pre-chilled T-per buffer by diluting the beads 1 : 1 with the buffer.
  • the slurry 200 ⁇ l was transferred to each tube containing the antibody-antigen mixture.
  • a control tube was set up by preparing a tube with 200 ⁇ l of slurry in 1 ml of T-Per buffer and 300 ⁇ g of antibody. The tubes were rotated at 4°C for 2 hours. Thereafter, the beads were washed twice using pre-chilled T-per buffer (centrifuged at 500 x g for 3 minutes) and the supernatants retained.
  • Calnexin is a 90 kD integral protein of the endoplasmic reticulum (ER). It consists of a large (50 kD) N-terminal calcium-binding lumenal domain, a single transmembrane helix and a short (90 residues), acidic cytoplasmic tail. Calnexin belongs to a family of proteins known as "chaperones,” which are characterized by their main function of assisting protein folding and quality control, ensuring that only properly folded and assembled proteins proceed further along the secretory pathway. The function of calnexin is to retain unfolded or unassembled N-linked glycoproteins in the endoplasmic reticulum.
  • Calnexin binds only those N-glycoproteins that have GlcNAc2Man9Glc 1 oligosaccharides. Oligosaccharides with three sequential glucose residues are added to asparagine residues of the nascent proteins in the ER. The monoglucosylated oligosaccharides that are recognized by calnexin result from the trimming of two glucose residues by the sequential action of two glucosidases, I and II. Glucosidase II can also remove the third and last glucose residue. If the glycoprotein is not properly folded, an enzyme called UGGT will add the glucose residue back onto the oligosaccharide thus regenerating the glycoprotein ability to bind to calnexin.
  • FIGS. 2OA and 2OB are screen shots depicting the read-out of the MS spectrograms identifying the protein of interest as calnexin.
  • Example 2 Microarray Analysis of Gene Expression in Tissues from Cohen Type 2 Diabetic Rats The microarray data were analyzed through Phase I and Phase II analyses. Phase I is based on the processed data from Gene Logic. Phase II corresponds to data analysis using GeneSpring GX. Additional criteria including statistics, signaling pathways and clustering were used for the analyses.
  • the global gene expression analysis showed that there were 1178 genes upregulated in CDr-HSD and 803 genes were downregulated in compared to CDs-HSD.
  • Many of these transcripts are involved in several signaling pathways related to Type 2 Diabtes such as insulin signaling, beta-cell dysfunction and lipid and glucose metabolisms.
  • serpin family members serpin family members (serine proteinase inhibitors) are expressed differently in the two models.
  • Table 10 provides a summary of the data derived from Gene Logic, wherein changes greater than 3 -fold were observed.
  • GeneSpring GX allows for gene lists to be filtered according to genes exhibiting a 2-fold or 3-fold change in the expression levels.
  • GeneSpring GX also comprises statistical algorithms, such as ANOVA, Post- Hoc Test, and Cross-Gene Error Modeling, as well as gene clustering algorithms like Gene Tree, K-mean clustering, and Self-Organizing Map (SOM) clustering.
  • GeneSpring GX also has the ability to integrate with pathways that are published in the art, such as the Kyoto Encyclopedia of Genes and Genomes (“KEGG pathways”) and Gen Map Annotator and Pathway Profiler (GenMAPP).
  • the microarray results analyzed by GeneSpring GX show that among the transcripts with changes higher than three fold in the two groups, 137 transcripts have a p-v&hie of less than 0.05. These genes are involved in several signaling pathways such as the insulin signaling pathway, serpin protein family, basic metabolism, pancreas function and inflammation.
  • Figure 21 shows a scatter plot of differentially expressed genes.
  • the 137 transcripts whose levels show a change of three-fold or higher are shown in Figure 22B and are also grouped in Tables 11 and 12.
  • Gene Tree gene clustering analysis shown in Figure 22A, shows the 12,729 genes that are present in all six samples. As discussed.above, 820 genes showed 2-fold changes in expression, while . 137 genes showed 3-fold changes in expression, and a Gene Tree representation is shown in Figure 22B.. Of the 137 genes that showed 3-fold changes, K-mean clustering analysis further divided these 137 genes into 5 sets, based on the greatest similarities between the genes within the sets (Figure 21C). These 5 sets are designated “Up-I”, “Up-2”, “Up-3", “Up-4", and "Up-5" and are summarized in Tables 13-17 below.
  • the protein encoded by the CD53 gene is a member of the transmembrane 4 superfamily. also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility.
  • This encoded protein is a cell surface glycoprotein that is known to complex with integrins. It contributes to the transduction of CD2-generated signals in T ceils and natural killer cells and has been suggested to play a role in growth regulation. Familial deficiency of this gene has been linked to an immunodeficiency associated with recurrent infectious diseases caused by bacteria, fungi and viruses.
  • CD38 is a novel multifunctional ectoenzyme widely expressed in cells and tissues especially in leukocytes. CD38 also functions in cell adhesion, signal transduction and calcium signaling.

Abstract

La présente invention concerne, d'une manière générale, l'identification de marqueurs biologiques associés à un accroissement des nsk dans le cas d'un diabète se développant, ainsi que des procédés d'utilisation desdits marqueurs biologiques dans le diagnostic et le pronostic du diabète. Les marqueurs biologiques de la présente invention peuvent indiquer de nouvelles cibles pour la thérapie ou constituer de nouvelles thérapies dans le traitement ou la prévention du diabète.
EP07754400A 2006-09-01 2007-03-28 Compositions et procédés pour le diagnostic et le traitement du diabète de type 2 Withdrawn EP2069768A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84171706P 2006-09-01 2006-09-01
PCT/US2007/007875 WO2008030273A2 (fr) 2006-09-01 2007-03-28 Compositions et procédés pour le diagnostic et le traitement du diabète de type 2

Publications (2)

Publication Number Publication Date
EP2069768A2 true EP2069768A2 (fr) 2009-06-17
EP2069768A4 EP2069768A4 (fr) 2010-01-20

Family

ID=39157723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07754400A Withdrawn EP2069768A4 (fr) 2006-09-01 2007-03-28 Compositions et procédés pour le diagnostic et le traitement du diabète de type 2

Country Status (6)

Country Link
EP (1) EP2069768A4 (fr)
JP (1) JP2010502946A (fr)
CN (1) CN101563597A (fr)
AU (1) AU2007293465A1 (fr)
CA (1) CA2661332A1 (fr)
WO (1) WO2008030273A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2010011860A1 (fr) 2008-07-23 2010-01-28 Diabetomics, Llc Procédé de détection du pré-diabète et du diabète
WO2010132447A2 (fr) 2009-05-11 2010-11-18 Diabetomics, Llc Procédés pour détecter un prédiabète et un diabète à l'aide de la glycosylation différentielle de protéines
JP5812701B2 (ja) * 2010-06-23 2015-11-17 アークレイ株式会社 血漿グルコース測定方法
WO2012000058A1 (fr) * 2010-07-02 2012-01-05 Newsouth Innovations Pty Limited Héritage d'un dysfonctionnement métabolique
SG10201806648TA (en) 2011-07-01 2018-09-27 Ngm Biopharmaceuticals Inc Compositions, uses and methods for treatment of metabolic disorders and diseases
US9963494B2 (en) 2012-11-28 2018-05-08 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN105008548B (zh) 2012-12-27 2020-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
LT3097122T (lt) 2014-01-24 2020-07-27 Ngm Biopharmaceuticals, Inc. Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai
CN103969234B (zh) * 2014-04-17 2017-02-15 山东东兴汇智生物科技有限公司 一种荧光素酶‑多抗原融合蛋白以及蛋白a琼脂糖‑融合蛋白‑抗体复合物
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CA2951153A1 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procedes et utilisations pour la modulation de l'homeostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
WO2016073855A1 (fr) * 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3003616C (fr) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methodes de traitement de troubles associes aux acides biliaires
CN106906278A (zh) * 2015-12-22 2017-06-30 复旦大学 预测ii型糖尿病心血管并发症风险的生物标记物及其用途
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN111758029B (zh) * 2018-02-27 2023-06-09 新加坡科技研究局 用于糖肽鉴定的方法、装置和计算机可读介质
CN108872293A (zh) * 2018-08-10 2018-11-23 厦门大学 一种肝泡型包虫病的代谢组学分析及初步筛查模型的构建方法
CN113539470A (zh) * 2020-04-14 2021-10-22 郑州大学第一附属医院 一种糖尿病肾病及非糖尿病性肾脏疾病鉴别诊断预测模型及构建方法
CN114404589B (zh) * 2021-12-24 2023-06-30 浙江大学 Rnase4作为治疗和/或预防糖尿病的药物靶点的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014151A2 (fr) * 2001-08-10 2003-02-20 Genset S.A. Adn complementaire et proteines humains et leurs utilisations
US20030073657A1 (en) * 2001-04-30 2003-04-17 Jorn-Peter Halle Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用
WO2004084797A2 (fr) * 2003-02-28 2004-10-07 Hubit Genomix Inc Gene associe au diabete sucre du type 2 et son utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088180A2 (fr) * 2001-04-30 2002-11-07 Switch Biotech Ag Utilisation de polypeptides alpha 1-antichymotrypsine ou d'acides nucleiques codant ces derniers, ou bien d'une cellule qui exprime un polypeptide act, ou d'un d'acide nucleique codant ce dernier, pour traiter et/ou prevenir les plaies se cicatrisant difficilement associees au diabete et/ou aux arteres et pour identifier d
US9062306B2 (en) * 2003-04-29 2015-06-23 Biocrine Ab Methods for identifying compounds for treating type 1 diabetes
WO2005094200A2 (fr) * 2003-06-20 2005-10-13 University Of Florida Biomarqueurs permettant de differencier des diabetes de types 1 et 2
JP2005337952A (ja) * 2004-05-28 2005-12-08 Kanazawa Univ Tlo Inc 生活習慣病予知因子
EP1615035B1 (fr) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Combinaisons de marqueurs pour détecter le diabete de type 1 et 2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073657A1 (en) * 2001-04-30 2003-04-17 Jorn-Peter Halle Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
WO2003014151A2 (fr) * 2001-08-10 2003-02-20 Genset S.A. Adn complementaire et proteines humains et leurs utilisations
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用
WO2004084797A2 (fr) * 2003-02-28 2004-10-07 Hubit Genomix Inc Gene associe au diabete sucre du type 2 et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008030273A2 *

Also Published As

Publication number Publication date
CA2661332A1 (fr) 2008-03-13
WO2008030273A3 (fr) 2008-08-28
AU2007293465A1 (en) 2008-03-13
EP2069768A4 (fr) 2010-01-20
CN101563597A (zh) 2009-10-21
WO2008030273A2 (fr) 2008-03-13
JP2010502946A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
EP2069768A2 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
EP2201370A2 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
US20100267052A1 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
US20180106817A1 (en) Protein biomarkers and therapeutic targets for renal disorders
JP2009511911A (ja) 糖尿病関連マーカおよびその使用
EP2834638B1 (fr) Procédés de diagnostic et de pronostic d'un sepsis
US20110319499A1 (en) Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
EP2924439B1 (fr) Ltbp2 comme biomarqueur pour la prediction ou le pronostic de la mortalite
EP3710831A1 (fr) Marqueurs pour le diagnostic et le traitement de la stéatohépatite non alcoolique (nash) et de la fibrose hépatique avancée
US20140302065A1 (en) Soluble urokinase receptor (supar) in diabetic kidney disease
EP2625202B1 (fr) Nouvelle méthode de diagnostic de l'hypertension et des cardiomyopathies
US20160202273A1 (en) Biomarkers associated with diabetes and fibrosis
EP3311164B1 (fr) Méthodes et compositions pour le diagnostic et le pronostic de l'appendicite et la différenciation des causes de la douleur abdominale
AU2010229767C1 (en) Markers related to age-related macular degeneration and uses therefor
AU2013201440B2 (en) Markers related to age-related macular degeneration and uses therefor
EP2882767B1 (fr) Évaluation d'une lésion rénale à l'aide de l'acide hyaluronique
EP2205978B1 (fr) Évaluation d'un risque d'insuffisance cardiaque congestive chez des patients traités ou pouvant être traités avec un agoniste du récepteur gamma activé par les proliférateurs des peroxysomes ou avec un thiazolidinedione

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090331

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIU, LIPING

Inventor name: GELBER, COHAVA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20091222

17Q First examination report despatched

Effective date: 20100406

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120225